A beta targeting proteins and methods of use

By designing Aβ-targeting proteins and utilizing the TfR binding region to deliver drugs across the blood-brain barrier, the drug delivery challenge in Alzheimer's disease treatment has been solved, achieving highly effective treatment with low side effects.

CN120958020APending Publication Date: 2025-11-14DENALI THERAPEUTICS INC
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202480021373.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-03-24
Filing Date
2024-03-22
Publication Date
2025-11-14

AI Technical Summary

Technical Problem

Existing treatments for Alzheimer's disease are ineffective at delivering drugs across the blood-brain barrier, and antibody therapy has side effects such as edema and microbleeds.

Method used

Develop an Aβ-targeting protein comprising an Aβ-binding domain, a transferrin receptor (TfR)-binding domain, and an FcγR-binding domain, which specifically binds to TfR with an affinity of approximately 900 nM to approximately 10,000 nM, thereby promoting drug delivery across the blood-brain barrier and reducing FcγR binding to decrease side effects.

Benefits of technology

It improves the rate of drug delivery to the brain, reduces side effects, especially the depletion of reticulocytes, and provides a safe and effective treatment option for Alzheimer's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005609815100000161
    Figure BDA0005609815100000161
  • Figure BDA0005609815100000301
    Figure BDA0005609815100000301
  • Figure BDA0005609815100000751
    Figure BDA0005609815100000751
Patent Text Reader

Abstract

Described herein are A [beta]-targeting proteins comprising an A [beta]-binding region; a transferrin receptor (TfR) binding region that specifically binds to the TfR with an affinity of from about 900 nM to about 10,000 nM; and an Fc [gamma] R binding region. Also described are methods of making the A [beta]-targeting proteins and methods of using the A [beta]-targeting proteins in the treatment of neurodegenerative disorders.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related applications

[0002] This application claims priority to U.S. Provisional Application No. 63 / 492,124, filed March 24, 2023. The entire contents of the above application are incorporated herein by reference.

[0003] sequence list

[0004] The sequence list written to file 590729_SeqListing_ST26.xml is 34 kilobytes in size, created on February 28, 2023, and is hereby incorporated by reference. Background of the Invention

[0006] Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by cognitive impairment, behavioral disturbances, psychiatric symptoms, and loss of activity of daily living. These clinical manifestations constitute AD dementia.

[0007] One of the hallmarks of this disease is the presence of β-amyloid plaques. It is speculated that the accumulation of Aβ plaques, caused by an imbalance between Aβ production and clearance in the brain, contributes to the pathogenesis.

[0008] The development of drugs for treating diseases such as Alzheimer's disease, requiring delivery to the brain, is complicated by the need for drug delivery across the blood-brain barrier. While several potential disease-mitigating drug candidates are under investigation, there are currently no reliable therapies to slow the progression of Alzheimer's disease. Antibodies targeting Aβ, while potentially offering some therapeutic benefits, also have side effects, including edema (VE) and microbleeds (mH). Therefore, there is a need in the art for improved therapeutic agents and methods for treating neurodegenerative conditions such as Alzheimer's disease. Summary of the Invention

[0009] An Aβ-targeting protein is described, comprising: (a) an Aβ-binding region, (b) a transferrin receptor (TfR)-binding region that specifically binds to TfR with an affinity of about 900 nM to about 10,000 nM, and (c) an FcγR-binding region. The Aβ-targeting protein is capable of crossing the blood-brain barrier and binding to β-amyloid. The TfR-binding region facilitates the transport of the Aβ-targeting protein across the blood-brain barrier, thereby promoting delivery to the brain. Contrary to predictions, the TfR-binding region, which specifically binds to TfR with an affinity of about 900 nM to about 10,000 nM, promotes the delivery of the β-amyloid-binding peptide to the brain, with an initial delivery rate higher than that of the β-amyloid-binding peptide linked to a TfR-binding peptide with a higher affinity for TfR. In some embodiments, the TfR binding region specifically binds TfR with an affinity of about 900 nM to about 8500 nM, about 900 nM to about 6500 nM, about 900 nM to about 5000 nM, about 900 nM to about 3500 nM, about 900 nM to about 2500 nM, about 900 nM to about 1600 nM, or about 900 nM to about 1300 nM. In some embodiments, the TfR binding region specifically binds TfR with an affinity of about 1000 nM to about 1200 nM. In some embodiments, the TfR binding region specifically binds TfR with an affinity of about 1100 nM.

[0010] In some embodiments, the TfR-binding region specifically binds to the apical domain of TfR. In some embodiments, the Aβ-targeting protein is configured such that the TfR-binding region binds to TfR without inhibiting the binding of transferrin to TfR. In some embodiments, the TfR is human TfR1.

[0011] TfR binding can be provided by, for example, a TfR-binding peptide, a TfR-binding peptide linked to an Fc peptide, a first Fc peptide comprising a CH3 domain modified to bind to TfR, an anti-TfR antibody or an antigen-binding fragment thereof, or an anti-TfR antibody or an antigen-binding fragment thereof linked to an Fc peptide. The Fc peptide can be derived from IgG, such as human IgG1, IgG2, IgG3, or IgG4. In some embodiments, TfR binding is provided by an Fc peptide comprising a CH3 domain having amino acid substitutions at at least six, seven, eight, nine, or ten positions selected from the EU numbering scheme: 380, 384, 386, 387, 388, 398, 390, 413, 415, 416, and 421 (e.g., N384Y, Q386T, P387E, E388W, N389V, D413T, S415E, R416E, and N421F). In some embodiments, TfR binding is provided by an Fc polypeptide comprising a CH3 domain having amino acid substitutions at eight, nine, or ten positions selected from the following: 380, 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421. In some embodiments, TfR binding is provided by an Fc polypeptide comprising a CH3 domain having, according to the EU numbering scheme, tyrosine or phenylalanine at position 384, threonine or asparagine at position 386, aspartic acid at position 387, tryptophan at position 388, serine, threonine, or valine at position 389, serine or asparagine at position 390, threonine or serine at position 413, serine or glutamine at position 415, glutamic acid at position 416, and phenylalanine or tyrosine at position 421. An exemplary CH3 domain modified to specifically bind TfR with an affinity of about 900 nM to about 10,000 nM (e.g., about 900 nM to about 2500 nM or about 900 nM to about 1300 nM) is provided by amino acids 348-453 or 348-454 of any of SEQ ID NO: 8, 10, and 17-31. In some embodiments, the TfR binding region comprises a CH3 domain having substitutions of any group listed in Table 1 and having an amino acid sequence having at least 85%, at least 90%, or at least 95% homology with amino acids 348-453 or 348-454 of any of SEQ ID NO: 8, 10, and 17-31.In some embodiments, the Fc polypeptide having a TfR binding region comprises a modified CH3 domain having at least 85%, at least 90%, or at least 95% identity with amino acids 348-454 of SEQ ID NO: 8 or 10 and having, according to the EU numbering scheme, tyrosine (Y) at position 384, threonine (T) at position 386, glutamic acid (E) at position 387, tryptophan (W) at position 388, valine (V) at position 389, threonine (T) at position 413, glutamic acid (E) at position 415, glutamic acid (E) at position 416, and phenylalanine (F) at position 421. In some embodiments, the Fc polypeptide having a TfR binding region comprises a modified CH3 domain having the amino acid sequence of amino acids 348-453 or 348-454 of any one of SEQ ID NO: 8, 10, and 17-31. In cases where TfR binding is provided by an antigen-binding fragment of an anti-TfR antibody, the fragment may be, but is not limited to, an F(ab)2 fragment, a Fab fragment, or a single-chain variable fragment (scFv).

[0012] FcγR binding can be provided by an Fc peptide. The Fc peptide can be derived from IgG, such as human IgG1, IgG2, IgG3, or IgG4. In some embodiments, the Fc peptide providing FcγR binding does not contain any modifications that reduce FcγR binding.

[0013] In some embodiments, the Aβ-targeting protein comprises an Fc dimer, wherein the dimer comprises a first Fc polypeptide and a second Fc polypeptide. In some embodiments, the Fc dimer is monovalent for TfR binding (i.e., the first or second Fc polypeptide (but not both) contains a TfR-binding region).

[0014] In some embodiments, the Aβ-targeting protein is configured to have reduced binding to FcγR when the Aβ-targeting protein binds to TfR. This reduced binding to FcγR when the Aβ-targeting protein binds to TfR can be achieved using an Fc dimer, wherein the first Fc polypeptide of the Fc dimer contains a CH3 domain modified to bind to TfR and one or more amino acid substitutions that reduce FcγR binding, and wherein the second Fc polypeptide of the Fc dimer does not bind to TfR and does not contain any modifications that reduce FcγR binding. According to the EU numbering scheme, mutations reducing FcγR binding include, but are not limited to, substitutions of L234A, L235A, and P329G (e.g., L234A and L235A substitutions or L234A, L235A, and P329G substitutions).

[0015] The Aβ-targeting protein containing the Fc dimer may have mutations in the Fc dimer polypeptide that promote heterodimerization. Such mutations include, but are not limited to, club-and-mortar mutations. According to the EU numbering scheme, the club mutation can be a T366W substitution. According to the EU numbering scheme, the mortar mutation can be, but is not limited to, T366S, T368A, and Y407V substitutions. One Fc polypeptide of the Fc dimer can be modified to have a club mutation, while the other Fc polypeptide of the Fc dimer can be modified to have a mortar mutation.

[0016] Exemplary Fc polypeptides suitable for forming Aβ-targeting proteins, having a TfR-binding region and one or more substitutions that reduce binding to FcγR, are provided by amino acids 228-453 or 228-454 of any of SEQ ID NO: 8, 10, and 17-31. In some embodiments, the Fc polypeptide having a TfR-binding region comprises a polypeptide having an amino acid sequence having at least 85%, at least 90%, or at least 95% homology with amino acids 228-453 or 228-454 of any of SEQ ID NO: 8, 10, and 17-31 and having amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1. In some embodiments, the Fc polypeptide having a TfR-binding region comprises a polypeptide having at least 85%, at least 90%, or at least 95% identity with amino acids 228-454 of SEQ ID NO: 8 or 10 and having, according to the EU numbering scheme, alanine at position 234, alanine at position 235, glycine optionally at position 329, tryptophan optionally at position 366, tyrosine at position 384, threonine at position 386, glutamic acid at position 387, tryptophan at position 388, valine at position 389, threonine at position 413, glutamic acid at position 415, glutamic acid at position 416, and phenylalanine at position 421. In some embodiments, the Fc polypeptide having a TfR-binding region comprises a polypeptide having the amino acid sequence of amino acids 228-453 or 228-454 of any one of SEQ ID NO: 8, 10, and 17-31.

[0017] Exemplary Fc polypeptides with an FcγR binding region suitable for forming Aβ-targeting proteins are provided by amino acids 228-454 of SEQ ID NO:9. In some embodiments, the Fc polypeptide with an FcγR binding region comprises a polypeptide having at least 85%, at least 90%, or at least 95% identity with amino acids 228-454 of SEQ ID NO:9, wherein, according to the EU numbering scheme, the polypeptide optionally has a serine at position 366, an alanine at position 368, and a valine at position 407. In some embodiments, the Fc polypeptide with an FcγR binding region comprises a polypeptide having the amino acid sequence of amino acids 228-453 or 228-454 of SEQ ID NO:9.

[0018] The Aβ-binding region of an Aβ-targeting protein can be, but is not limited to, an anti-Aβ antibody with its antigen-binding region. In some embodiments, anti-AβFab binds to β-amyloid plaques and fibrils. The anti-Aβ antibody with its antigen-binding region can be derived from anti-Aβ antibodies known in the art. In some embodiments, the Aβ-binding region of the Aβ-targeting protein comprises a CDR sequence of an anti-Aβ antibody known in the art. The antigen-binding region can be, but is not limited to, Fab (or F(ab)2) or scFv. In some embodiments, the Aβ-binding region comprises anti-AβFab. In some embodiments, anti-AβFab is linked to an Fc polypeptide having a TfR-binding region or an FcγR-binding region. In some embodiments, the Aβ-targeting protein comprises a first anti-AβFab linked to a first Fc polypeptide having a TfR-binding region and a second anti-AβFab linked to a second Fc polypeptide having a second Fc polypeptide having an FcγR-binding region, wherein the first and second Fc polypeptides form an Fc dimer.

[0019] In some embodiments, the Aβ-targeting protein comprises two antibody light chains; a first antibody heavy chain comprising an Fc polypeptide having a CH3 domain modified to have a TfR-binding region and optionally one or more mutations that reduce FcγR binding; and a second antibody heavy chain comprising an Fc polypeptide having an FcγR-binding region.

[0020] In some embodiments, the Aβ-targeting protein binds to Aβ and mediates effector function via the FcγR receptor-binding domain. In some embodiments, the Aβ-targeting protein binds to amyloid plaques, cerebral vascular Aβ, or diffuse Aβ deposits and mediates effector function via the FcγR receptor-binding domain. In some embodiments, the Aβ-targeting protein is configured to have reduced FcγR receptor binding when the Aβ-targeting protein binds to TfR. In some embodiments, the Aβ-targeting protein does not significantly deplete reticulocytes when administered to a subject in vivo.

[0021] Any of the Aβ-targeting proteins can be provided in a pharmaceutically acceptable composition. A pharmaceutically acceptable composition may contain one or more pharmaceutically acceptable excipients. The pharmaceutical composition may be formulated for use in combination with additional agents that can be used to treat neurodegenerative diseases, such as Alzheimer's disease.

[0022] Provides a nucleic acid encoding an Aβ-targeting protein. In some embodiments, the nucleic acid encoding the Aβ-targeting protein antibody heavy chain encodes a polypeptide having at least 85%, at least 90%, or at least 95% identity with any of SEQ ID NO: 8, 10, and 17-31, wherein said encoded polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1 ... NO:8 or 10 has a polypeptide with at least 85% consistency, at least 90% consistency, or at least 95% consistency, wherein the encoded polypeptide contains: (a) alanine at position 234, alanine at position 235, glycine at position 329, tryptophan at position 366, tyrosine at position 384, threonine at position 386, glutamic acid at position 387, tryptophan at position 388, valine at position 389, threonine at position 413, and at position 415... The amino acid at position 413, glutamic acid at position 415, glutamic acid at position 416, and phenylalanine at position 421; or (b) alanine at position 234, alanine at position 235, tryptophan at position 366, tyrosine at position 384, threonine at position 386, glutamic acid at position 387, tryptophan at position 388, valine at position 389, threonine at position 413, glutamic acid at position 415, glutamic acid at position 416, and phenylalanine at position 421. In some embodiments, the nucleic acid encoding the heavy chain of the Aβ-targeting protein antibody encodes a polypeptide having the amino acid sequence of any one of SEQ ID NO: 8, 10, and 17-31.

[0023] Cells comprising all or a portion of one or more nucleic acids encoding Aβ-targeting proteins are also described. In some embodiments, the cell comprises: (a) a first nucleic acid encoding a polypeptide having at least 85%, at least 90%, at least 95%, or 100% similarity to any one of SEQ ID NO:8, 10, and 17-31; (b) a second nucleic acid encoding a polypeptide having at least 85%, at least 90%, at least 95%, or 100% similarity to SEQ ID NO:9; and (c) a third nucleic acid encoding a polypeptide having at least 85%, at least 90%, at least 95%, or 100% similarity to SEQ ID NO:7.

[0024] A method for producing an Aβ-targeting protein is described, comprising: culturing a host cell containing one or more nucleic acids encoding an Aβ-targeting protein under conditions suitable for nucleic acid expression, and isolating the Aβ-targeting protein from the culture.

[0025] A method for reducing amyloid plaques in the brain of a subject is described, the method comprising administering an Aβ-targeting protein to the subject. The Aβ-targeting protein may be administered to subjects who have cognitive impairment, memory loss, dementia, or loss of neuronal connectivity in the brain, or who have a disease associated with the accumulation of Aβ or amyloid plaques, or who are at risk of developing said disease. In some embodiments, the subject has or has been diagnosed with Alzheimer's disease or is at an increased risk of developing Alzheimer's disease.

[0026] A method for treating a subject with a neurodegenerative disease is described, comprising administering an Aβ-targeting protein to the subject. In some embodiments, the neurodegenerative disease is Alzheimer's disease. In some embodiments, the method further comprises administering at least one additional agent to the subject that can be used to treat Alzheimer's disease.

[0027] A method for increasing Aβ phagocytosis and / or increasing microglia recruitment to Aβ-positive plaques in subjects is described, comprising administering an Aβ-targeting protein to the subject.

[0028] A method for reducing amyloid-associated imaging abnormalities (ARIA) in subjects is described, which involves administering an Aβ-targeting protein to the subjects. Attached Figure Description

[0029] Figure 1 Explain the relationship between ATV and oligomeric Aβ. 1-42 and fibrous Aβ 1-42 and monomer Aβ 1-40 A diagram combining [elements].

[0030] Figures 2A-C illustrate the following: Injected dose of Aβ-targeting protein ATV35.23.3 顺式LALA Aβ and ATV35.23.4 顺式LALA :A) plasma clearance and (B) neuropharmacokinetics (PK) of Aβ and (C) in TfR mu / hu In mice, administration of the Aβ-targeting protein ATV35.23.3 cis-... LALA :Aβ and ATV35.23.4:Aβ-reticulocytes.

[0031] Figure 2D-G. A diagram illustrating the following situation: in TfR mu / hu Mice were injected with anti-Aβ IgG antibody, ATV35.23.3:Aβ, and ATV35.23.3. 顺式LALA :Aβ or ATV35.23.3 LALA (D) Human IgG concentration in plasma after Aβ, (E) Human IgG concentration in the brain, (F) Blood reticulocyte level, or (G) Bone marrow reticulocyte level.

[0032] Figure 3. (A) Illustration of the implementation scheme of the Aβ-targeting protein. (B) Graph illustrating the brain IgG concentration of the Aβ-targeting protein shown in A. (C) Illustration of TfR mu / hu A graph showing the effect of administration of the Aβ-targeting protein shown in A on blood reticulocytes in mice.

[0033] Figure 4. A diagram illustrating the following situation: In the App SAA KI TfR mu / hu Mice were administered anti-AβIgG and ATV: 35.23.4. 顺式LALA Aβ and ATV35.23.3 顺式LALA The following parameters were determined after Aβ: (A) plasma huIgG level, (B) brain huIgG level, (C) huIgG intensity in plaques, (D) percentage of plaques coexisting with CD68, and (E) percentage of plaque area.

[0034] Figure 5 A graph illustrating plasma PK after administration of the indicated ATV:Aβ molecule to wild-type mice.

[0035] Figure 6A A graph illustrating the dynamic light scattering analysis of fluorescein (FAM) labeled β-amyloid protein 1-42 fibrils.

[0036] Figure 6B Explanation of TfR after administration of ATV:Aβ molecules. mu / hu A graphic illustration of FACS analysis of FAM-labeled β-amyloid fibrils in mice.

[0037] Figures 6C-D illustrate the following situations: in TfR mu / hu (C) Aβ-positive microglia and (D) Aβ signal intensity in microglia after injection of the indicated ATV:Aβ molecule in mice.

[0038] Figure 7. A diagram illustrating the following situation: In the APP SAA KI; TfR mu / hu (A) Immunodecoration analysis, (B) Microglial recruitment to plaques, and (C) Total plaque area after injection of the indicated ATV:Aβ molecule into KI mice.

[0039] Figure 8A-B. Graph illustrating the levels of (A) blood reticulocytes and (B) heme in non-human primates after injection of the indicated ATV:Aβ molecule. Figure 8C (See the illustration shown).

[0040] Figure 8C A graph illustrating erythrocyte levels in non-human primates after administration of the indicated ATV:Aβ molecule.

[0041] Figure 9 A graph illustrating plasma PK in non-human primates after administration of the indicated ATV:Aβ molecule.

[0042] Figure 10A This indicates the use of ATV35.23.4. 顺式LALA ATV35.23.4 顺式LALAPG Or 5XFAD with control IgG treatment; TfR mu / hu A diagram showing the plasma PK profile in KI mice.

[0043] Figure 10B-D. Diagram illustrating the following situation: (B) ATV35.23.4 顺式LALA ATV35.23.4 顺式LALAPG Or, compare the brain concentration of IgG, (C)ATV 35.23.4 顺式LALA ATV35.23.4 顺式LALAPG Or, compare the immunomodulation of plaques with control IgG, and (D) with ATV35.23.4. 顺式LALA ATV35.23.4 顺式LALAPG Or, after comparison with IgG, CD68 is directed towards 35-125 μm. 2 Plaque recruitment.

[0044] Figure 11The administration of anti-AβhIgG (10 mg / kg), anti-AβkLALAhIgG (10 mg / kg), ATV35.23.3:Aβ (3 mg / kg), and ATV35.23.3 was described. 顺式LALA The number of 5xFAD:TfRmu / huKI mice that exhibited ARIA events after Aβ (3 mg / kg).

[0045] Figure 12 The study depicted the different pathways by which anti-Aβ and ATV:Aβ enter the brain due to the preferential expression of TfR in capillaries and venules. Consequently, ATV:Aβ exhibited a broader biodistribution in the brain parenchyma (cyan), while anti-Aβ remained predominantly distributed in the cerebrovascular system one day after a single peripheral injection. Detailed Implementation

[0046] I. Definition

[0047] As used herein, unless the context clearly indicates otherwise, the singular forms “a / an” and “the” include multiple indicators. Thus, for example, references to “polypeptide” can include two or more such molecules, etc.

[0048] As used herein, the terms “about” and “approximately”, when used to modify a quantity specified in a numerical value or range, indicate the numerical value and a reasonable deviation from the value known to a person skilled in the art. In some embodiments, the term “about” means within the typical range of tolerances in the art. In some embodiments, the term “about” means within 1 or 2 standard deviations of the mean. In some embodiments, the term “about” means ±10%. In some embodiments, the term “about” means ±5%. When the term “about” precedes a series of numbers or ranges, it should be understood that “about” may modify each number in that series or range.

[0049] As used in the context of this invention, “transferrin receptor” or “TfR” refers to transferrin receptor protein 1. The human transferrin receptor 1 polypeptide sequence is shown in SEQ ID NO:15. Transferrin receptor protein 1 sequences from other species are also known (e.g., chimpanzee, accession number XP 003310238.1; rhesus monkey, NP_001244232.1; dog, NP_001003111.1; bovine, NP_001193506.1; mouse, NP 035768.1; rat, P_073203.1; and chicken, P_990587.1). The term “transferrin receptor” also covers allelic variants of exemplary reference sequences (e.g., human sequences) encoded by genes at the chromosomal locus of transferrin receptor protein 1. The full-length transferrin receptor protein comprises a short N-terminal intracellular region, a transmembrane region, and a large extracellular domain. The extracellular domain is characterized by three domains: a protease-like domain, a helical domain, and a apical domain. The apical domain sequence of human transferrin receptor 1 is shown in SEQ ID NO:4.

[0050] "Fc polypeptide" refers to the C-terminal region of a naturally occurring immunoglobulin heavy chain polypeptide, characterized by an Ig fold as a structural domain. Fc polypeptides contain a constant region sequence including at least a CH2 domain and / or a CH3 domain, and may contain at least a portion of a hinge region. Generally, Fc polypeptides do not contain variable regions.

[0051] "Modified Fc polypeptide" is an Fc polypeptide that has at least one mutation (e.g., substitution, deletion, or insertion) compared to the wild-type immunoglobulin heavy chain Fc polypeptide sequence, but retains the overall Ig fold or structure of the native Fc polypeptide.

[0052] An "Fc polypeptide dimer" refers to a dimer of two Fc polypeptides. In some embodiments, the Fc polypeptide dimer is capable of binding to an Fc receptor (e.g., FcγR). In an Fc polypeptide dimer, the two Fc polypeptides dimerize through the interaction between two CH3 antibody constant domains. In some embodiments, the two Fc polypeptides may also dimerize through one or more disulfide bonds formed between the hinge domains of the two dimerizing Fc domain monomers. The Fc polypeptide dimer can be a heterodimer or a homodimer. An Fc polypeptide dimer can comprise two wild-type Fc polypeptides, one wild-type Fc polypeptide and one modified Fc polypeptide, or two modified Fc polypeptides. For an Fc polypeptide dimer comprising two modified Fc polypeptides, the two modified Fc polypeptides can be the same or different.

[0053] As used herein, the terms “CH3 domain” and “CH2 domain” refer to the constant region polypeptide of an immunoglobulin. In the case of IgG antibodies, the CH3 domain polypeptide refers to the amino acid segment from approximately position 341 to position 447, as numbered according to the EU numbering scheme, and the CH2 domain polypeptide refers to the amino acid segment from approximately position 231 to position 340, as numbered according to the EU numbering scheme. The CH2 and CH3 domain polypeptides may also be numbered according to the IMGT Scientific chart numbering (IMGT website) using the EVIGT (ImMunoGeneTics) numbering scheme, where the CH2 domain is numbered 1-110 and the CH3 domain is numbered 1-107. The CH2 and CH3 domains are part of the Fc region of an immunoglobulin. In the context of IgG antibodies, the Fc region refers to the amino acid segment from approximately position 231 to position 447, as numbered according to the EU numbering scheme. As used herein, the term “Fc region” may also include at least a portion of the antibody hinge region.

[0054] The terms “wild-type,” “natural,” and “naturally occurring” for CH3 or CH2 domains are used in this document to refer to domains that have sequences that are naturally occurring.

[0055] The term "Fcγ receptor" or "FcγR" refers to a type of Fc receptor, classified based on the types of antibodies they recognize. FcγR includes several members: FcγRI (CD64), FcγRIIA (CD32), FcγRIIB (CD32), FcγRIIIA (CD16a), and FcγRIIIB (CD16b), which differ in antibody affinity due to their different molecular structures. FcγR binds to the Fc portion of IgG antibodies and is crucial for inducing opsonization of microorganisms. FcγR is found on the cell surface of cells in the immune system. FcγR is responsible for triggering immune system effector functions and is activated upon binding of the antibody's Fc portion to its receptor. FcγR mediates immune functions, such as binding to antibodies attached to infected cells or invading pathogens, stimulating phagocytes or cytotoxic cells to destroy microorganisms or infected cells through antibody-mediated phagocytosis or ADCC.

[0056] The term "variable region" refers to a domain in the antibody heavy or light chain derived from germline variable (V) genes, diversity (D) genes (heavy chain only), and linker (J) genes (and not derived from constant (Cμ and Cδ) gene segments), which confers the antibody's specificity for binding to the antigen. Typically, the antibody variable region contains four conserved "framework" regions interspersed with three hypervariable "complementarity-determining regions" (CDRs).

[0057] A variant of a given sequence is a change in the nucleic acid or amino acid sequence relative to a reference (e.g., wild-type or most common) sequence. Variants can be naturally occurring sequences (e.g., allelic variants) or non-naturally occurring sequences. Non-naturally occurring variant domains are variant or mutant domains that do not exist in cells in nature and are produced through genetic modification of natural domains (e.g., using genetic engineering or mutagenesis techniques). Changes in the nucleic acid or amino acid sequence (e.g., mutations) can include one or more substitutions, one or more insertions, one or more deletions, or combinations thereof.

[0058] The terms “conservative substitution,” “conservative mutation,” or “variant of conserved modification” refer to a change that results in the substitution of one amino acid with another amino acid that can be classified as having similar characteristics. Examples of conserved amino acid group categories defined in this way may include: “charged / polar groups,” including Glu (glutamic acid or E), Asp (aspartic acid or D), Asn (asparagine or N), Gln (glutamine or Q), Lys (lysine or K), Arg (arginine or R), and His (histidine or H); “aromatic groups,” including Phe (phenylalanine or F), Tyr (tyrosine or Y), Tip (tryptophan or W), and (histidine or H); and “aliphatic groups,” including Gly (glycine or G), Ala (alanine or A), Val (valine or V), Leu (leucine or L), He (isoleucine or I), Met (methionine or M), Ser (serine or S), Thr (threonine or T), and Cys (cysteine ​​or C). Within each group, subgroups can also be identified. For example, charged or polar amino acid groups can be further subdivided into subgroups, including: a "positively charged subgroup" containing Lys, Arg, and His; a "negatively charged subgroup" containing Glu and Asp; and a "polar subgroup" containing Asn and Gln. In another example, aromatic or cyclic groups can be subdivided into subgroups, including: a "nitrogen-cyclic subgroup" containing Pro, His, and Trp; and a "phenyl subgroup" containing Phe and Tyr. In yet another further example, aliphatic groups can be subdivided into subgroups, such as: a "liphatic nonpolar subgroup" containing Val, Leu, Gly, and Ala; and a "liphatic slightly polar subgroup" containing Met, Ser, Thr, and Cys. Examples of conserved mutation categories include amino acid substitutions within the aforementioned subgroups, such as, but not limited to: Lys for Arg, or vice versa, to maintain a positive charge; Glu for Asp, or vice versa, to maintain a negative charge; Ser for Thr, or vice versa, to maintain free -OH; and Gln for Asn, or vice versa, to maintain free -NH2. In some embodiments, the hydrophobic amino acid substitutes for a naturally occurring hydrophobic amino acid at the active site, for example, to maintain hydrophobicity.

[0059] "Binding affinity" refers to the strength of the non-covalent interaction between two molecules, such as a single binding region or site on a protein, and a target. Binding affinity can be quantified by measuring the equilibrium dissociation constant (KD), which is the dissociation rate constant (k... d ,time -1 Divide by the association rate constant (k) a ,time -1 M -1 KD can be determined by measuring the kinetics of complex formation and dissociation, for example using surface plasmon resonance (SPR) methods, such as Biacore. TM System; kinetic exclusion measurement, such as and BioLayer intervention (e.g., using) Platform). The term "binding affinity" includes not only formal binding affinity, such as binding affinity reflecting a 1:1 interaction between a peptide and its target, but also apparent affinity calculated using KD, which reflects affinity binding (affinity).

[0060] When referring to binding regions (e.g., Aβ-binding regions, TfR-binding regions, or FcγR-binding regions), the terms "specific binding" or "selective binding" to a target (e.g., β-amyloid, TfR, or FcγR) refer to a binding response in which the binding region binds to a target with a greater affinity, stronger affinity, and / or longer duration than it binds to a structurally different target. When measured under the same affinity assay conditions, the binding region may exhibit at least 5, 6, 7, 8, 9, 10, 20, 25, 50, 100, 1,000, 10,000, or greater affinity for a specific target compared to an unrelated target. The terms "specific binding to a specific target," "specifically binding to a specific target," or "specific to a specific target" can be defined, for example, by the equilibrium dissociation constant KD of the molecule with respect to the target it binds to (e.g., 10...). -4 M or smaller (e.g., 10) -5 M, 10 -6 M(1000nM), 10 -7 M(100nM), 10 -8 M(10nM), 10 -9 M(1nM), 10 -10 M, 10 -11 M or 10 -12 M)) is used to represent this. In some implementations, the binding region specifically binds to interspecies conserved (e.g., interspecies structurally conserved) targets (e.g., proteins).

[0061] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimics that function in a manner similar to naturally occurring amino acids.

[0062] Naturally occurring amino acids are those encoded by the genetic code, as well as those modified later, such as hydroxyproline, γ-carboxyglutamic acid, and O-phosphoserine. "Amino acid analogs" are compounds that have the same basic chemical structure as naturally occurring amino acids (i.e., the carbon atom bound to hydrogen, carboxyl, amino, and R groups), such as homoserine, ortholeucine, methionine sulfoxide, and methionine methylsulfonium. These analogs may have modified R groups (e.g., ortholeucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. "Amino acid mimics" are compounds that have a structure different from the general chemical structure of amino acids, but function in a manner similar to naturally occurring amino acids.

[0063] Naturally occurring α-amino acids include, but are not limited to, alanine (Ala), cysteine ​​(Cys), aspartic acid (Asp), glutamic acid (Glu), phenylalanine (Phe), glycine (Gly), histidine (His), isoleucine (He), arginine (Arg), lysine (Lys), leucine (Leu), methionine (Met), asparagine (Asn), proline (Pro), glutamine (Gln), serine (Ser), threonine (Thr), valine (Val), tryptophan (Trp), tyrosine (Tyr), and combinations thereof. Naturally occurring stereoisomers of α-amino acids include, but are not limited to, D-alanine (D-Ala), D-cysteine ​​(D-Cys), D-aspartic acid (D-Asp), D-glutamic acid (D-Glu), D-phenylalanine (D-Phe), D-histidine (D-His), D-isoleucine (D-Ile), D-arginine (D-Arg), D-lysine (D-Lys), D-leucine (D-Leu), D-methionine (D-Met), D-asparagine (D-Asn), D-proline (D-Pro), D-glutamine (D-Gln), D-serine (D-Ser), D-threonine (D-Thr), D-valine (D-Val), D-tryptophan (D-Trp), D-tyrosine (D-Tyr), and combinations thereof. Amino acids are referred to herein by their commonly known three-letter symbols or by the single-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Committee.

[0064] As used herein, the term "mutant" in relation to mutant polypeptides or mutant polynucleotides may be used interchangeably with "variant." A variant of a given wild-type CH3 or CH2 domain reference sequence may include naturally occurring allelic variants. A "non-naturally occurring" CH3 or CH2 domain refers to a variant or mutant domain that is not present in cells in nature and is produced through genetic modification of a natural CH3 or CH2 domain polynucleotide or polypeptide (e.g., using genetic engineering or mutagenesis techniques). A "variant" includes any domain containing at least one amino acid mutation relative to the wild type. Mutations may include substitutions, insertions, and deletions. A single amino acid substitution may be indicated by a single-letter amino acid symbol indicating the amino acid before substitution, followed by a number indicating the amino acid position, and then a single-letter amino acid symbol indicating the amino acid substitution (e.g., T366W indicates that threonine at position 366 has been modified to tryptophan). A single amino acid substitution may also be indicated by a number indicating the position of the amino acid that is substituted, followed by a single-letter amino acid symbol indicating the amino acid substitution (e.g., 366W indicates tryptophan at position 366).

[0065] A "peptide" is a polymer of two or more amino acid residues in a single chain. This term applies to amino acid polymers that are artificial chemical mimics of the corresponding naturally occurring amino acids, as well as both naturally occurring and non-naturally occurring amino acid polymers. Amino acid polymers can contain only L-amino acids, only D-amino acids, or a mixture of L and D amino acids.

[0066] As used herein, the term "protein" refers to a polypeptide, polypeptide dimer, or polypeptide multimer. A polypeptide dimer can be a homodimer or a heterodimer. A polypeptide multimer can be a homopolymer or a heteropolymer. A heteropolymer can contain two or more duplicates of any given single-chain polypeptide. For example, immunoglobulins are heteropolymers containing two heavy chains and two light chains. The two heavy chains can be the same or different, and the two light chains can be the same or different. The individual polypeptide chains of a dimer or multimer can be linked by one or more covalent bonds (e.g., disulfide bonds), by non-covalent interactions, or by a combination thereof.

[0067] In the context of two or more nucleic acid or polypeptide sequences, the term "consistency" or "percentage of consistency" refers to two or more sequences or subsequences that are identical or have a specified percentage (e.g., at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% or greater) of nucleic acid or amino acid residues that are consistent in a specified region when compared and aligned within a comparison window or specified region to obtain maximum correspondence, as measured by using sequence alignment algorithms or by manual alignment and visual inspection. For sequence alignment, typically one sequence serves as a reference sequence for comparison with a candidate sequence. Alignments can be performed using known algorithms to achieve maximum alignment using various methods available to those skilled in the art (e.g., visual alignment) or publicly available software. Such programs include BLAST, ALIGN, ALIGN-2 (Genentech, South San Francisco, Calif.), or Megalign (DNASTAR). The parameters used for alignment to achieve maximum alignment can be determined by those skilled in the art. For sequence comparison of polypeptide sequences for the purposes of this application, the BLASTP algorithm standard protein BLAST is used to align two protein sequences with the default parameters.

[0068] When used in the context of identifying a given nucleotide or amino acid residue in a nucleic acid or polypeptide sequence, the terms "corresponding to," "reference determined," or "reference number" specify the position of a residue in the reference sequence when the given amino acid sequence is aligned and compared to a reference sequence to the greatest extent possible. The sequence aligned to the reference sequence does not need to be the same length as the reference sequence.

[0069] In this art, the “EU numbering scheme” is commonly used when referring to residues in the constant region of the antibody heavy chain. The EU numbering scheme for SEQ ID NO:8 is as follows:

[0070]

[0071] As used interchangeably in this document, the terms “subject,” “individual,” and “patient” refer to mammals, including but not limited to humans, non-human primates, rodents (e.g., rats, mice, and guinea pigs), rabbits, cattle, pigs, horses, and other mammal species. In some embodiments, the subject is a human.

[0072] The terms "treat" or "treatment" mean a method or procedure taken to alleviate, reduce, or improve the quantity, severity, adverse effects, and / or frequency of one or more symptoms or pathological consequences of a subject's disease, condition, or disorder. Treatment can be preventative in relation to the prevention or partial prevention of a disease, or its symptoms or disorders. Prevention includes providing prevention of the onset or recurrence of the disease in subjects who may be susceptible to the disease but have not yet been diagnosed with it. Prevention also includes providing prevention of the onset or recurrence of the symptoms or pathological consequences of the disease in subjects who may be susceptible to the symptoms or pathological consequences of the disease but have not yet been diagnosed with them. Treatment can also be preventative in relation to delaying the onset of a disease or its symptoms or disorders. Delaying the development of a disease or its symptoms or pathological consequences indicates delaying, hindering, mitigating, slowing, stabilizing, inhibiting, and / or postponing the development of the disease or its symptoms or pathological consequences. Delays can have varying durations, depending on the disease history and / or the individual being treated. Treatment may include suppressing a disease, symptom, or disorder, such as preventing its progression; and alleviating said disease, symptom, or disorder, such as causing its remission. Treatment may also mean prolonging survival compared to expected survival without treatment. Treatment may be therapeutic in relation to partial or complete cure of a disease, disorder, symptom, or adverse effect attributable to a disease, symptom, or disorder. The term treatment may include: (a) preventing the occurrence of said disease in subjects who may be susceptible to it but have not yet been diagnosed with it; (b) suppressing the disease, i.e., preventing its development; and (c) alleviating said disease, i.e., reducing or improving said disease and / or its symptoms or disorder. Treatment may refer to therapeutic treatment alone, preventive treatment alone, or both therapeutic and preventive treatment. Those who require treatment (subjects in need) may include those previously diagnosed with a disease, symptom, or disorder, or those identified as being at risk of developing a disease, symptom, or disorder. Treating a disease, symptom, or disorder may include improving at least one symptom of a particular disease, symptom, or disorder, even if the underlying pathophysiology is unaffected.

[0073] The term "pharmacologically acceptable excipient" refers to an inactive pharmaceutical ingredient that is biologically or pharmacologically suitable for human or animal use, such as, but not limited to, buffers, carriers, or preservatives.

[0074] In the context of administration, the “effective amount” of an agent (e.g., an Aβ-targeting protein or a pharmaceutical preparation containing an Aβ-targeting protein) refers to the amount that, at the necessary dose / amount and for the necessary duration, is effective in achieving the desired outcome, such as a therapeutic or preventative outcome.

[0075] The "therapeutic effective amount" of an agent (such as an Aβ-targeting protein or a pharmaceutical preparation containing an Aβ-targeting protein) refers to the amount that effectively achieves the desired therapeutic outcome within the necessary dose and time period, such as for the treatment of a disease, ailment, or condition, and / or the pharmacokinetic or pharmacodynamic effects of treatment. Therapeutic effective amounts can vary based on factors such as the subject's disease state, age, sex, weight, and the cell population administered.

[0076] "Dose," "unit dose," or "dosage" refers to a physically discrete unit applicable to a subject, each unit containing a predetermined amount of the active pharmaceutical ingredient and / or pharmaceutical composition.

[0077] The term "administration" refers to a method of delivering an agent, compound, or composition to a desired biological site of action. These methods include, but are not limited to, local delivery, parenteral delivery, intravenous delivery, intradermal delivery, intramuscular delivery, intrathecal delivery, colonic delivery, rectal delivery, or intraperitoneal delivery. In one embodiment, the composition described herein is administered intravenously.

[0078] II. Aβ-targeting protein

[0079] The binding of the transferrin receptor-binding region to a molecule can be used to increase molecular delivery across the blood-brain barrier (BBB). For some molecules, such as antisense oligonucleotides, rapid delivery to the brain is preferred. For other compounds, initial delivery rate is less important than persistence. TfR-binding peptides with high affinity for TfR (e.g., binding affinity less than 900 nM) generally result in high initial delivery rates to the brain, followed by rapid clearance. In contrast, TfR-binding peptides with low affinity for TfR generally have lower initial delivery rates to the brain compared to higher affinity TfR-binding peptides, but increased brain persistence. Surprisingly, the linking of a TfR-binding peptide with an affinity of about 900 nM to about 10,000 nM (e.g., about 900 nM to about 2,500 nM or about 900 nM to about 1,300 nM) to a β-amyloid-binding peptide resulted in a higher initial rate (Cmax) of delivery of the β-amyloid-binding peptide to the brain compared to the initial delivery rate of a β-amyloid-binding peptide linked to a TfR-binding peptide with a higher affinity for Tfr.

[0080] An Aβ-targeting protein and composition capable of crossing the blood-brain barrier and binding to β-amyloid plaques are described. The Aβ-targeting protein comprises an Aβ-binding region, a TfR-binding region specifically binding to TfR with an affinity of about 900 nM to about 10,000 nM (e.g., about 900 nM to about 2500 nM or about 900 nM to about 1300 nM), and an FcγR-binding region. The Aβ-targeting protein is delivered across the blood-brain barrier (BBB). Due to its Aβ-binding and immune effector properties, the Aβ-targeting protein can be administered to a subject to treat amyloid plaques. Contrary to expectations, the use of TfR-binding regions that specifically bind TfR with an affinity of about 900 nM to about 10,000 nM (e.g., about 900 nM to about 2500 nM or about 900 nM to about 1300 nM), when linked to Aβ-binding peptides, resulted in increased protein delivery to the brain, and to a greater extent than TfR-binding regions with higher TfR affinity. Furthermore, TFR-binding regions that specifically bind TfR with an affinity of about 900 nM to about 10,000 nM (e.g., about 900 nM to about 2500 nM or about 900 nM to about 1300 nM) also exhibited increased brain retention of Aβ-targeting proteins when linked to Aβ-binding peptides. The combination of higher initial brain delivery rates and higher brain retention is useful for therapies aimed at targeting β-amyloid plaques and fibrils.

[0081] The invention describes an Aβ-targeting protein, a composition containing the Aβ-targeting protein, a nucleic acid encoding the Aβ-targeting protein, and a method for manufacturing the Aβ-targeting protein.

[0082] Methods of treating diseases or disorders mediated by β-amyloid protein using Aβ-targeting proteins, including neurodegenerative diseases such as Alzheimer's disease.

[0083] A. β-amyloid (Aβ) binding region

[0084] β-amyloid (Aβ) is a peptide of 36-43 amino acids in length and is the main component of amyloid plaques (extracellular deposits) found in the brains of people with Alzheimer's disease. These plaques consist of tangled Aβ oligomers and regularly ordered aggregates called amyloid fibrils. Soluble oligomeric forms of Aβ may be a contributing factor to the development of Alzheimer's disease.

[0085] The Aβ-binding region contains a polypeptide, region, or domain that specifically binds to Aβ, or a polypeptide or protein. The Aβ-binding region may specifically bind to oligomeric Aβ and / or fibrillary Aβ. In some embodiments, the Aβ-binding region binds to oligomeric Aβ. In some embodiments, the Aβ-binding region binds to fibrillary Aβ. In some embodiments, the Aβ-binding region binds to both oligomeric Aβ and fibrillary Aβ.

[0086] Aβ-targeting proteins can be monovalent or polyvalent for Aβ binding. In other words, an Aβ-targeting protein may contain a single Aβ-binding region or multiple Aβ-binding regions. In some embodiments, an Aβ-targeting protein comprises two or more Aβ-binding regions. The two or more Aβ-binding regions may be the same or different. In some embodiments, an Aβ-targeting protein comprises two Aβ-binding regions.

[0087] The Aβ binding region can be, but is not limited to, a peptide, an engineered peptide, an anti-Aβ antibody, or an Aβ-binding fragment of an anti-Aβ antibody.

[0088] Anti-Aβ antibodies are known in the art and are available from various commercial sources. Anti-Aβ may be an antibody against Aβ from a non-human species, with the limitation that the antibody binds to human Aβ. In some embodiments, the anti-Aβ antibody or the Aβ-binding fragment of the anti-Aβ antibody binds to oligomeric Aβ and fibrillary Aβ.

[0089] The Aβ-binding fragment of an anti-Aβ antibody can be, but is not limited to, an F(ab)2 fragment, a Fab fragment, or a single-chain variable fragment (scFv).

[0090] In some embodiments, the Aβ-binding region comprises an antigen-binding domain of an anti-Aβ antibody. In some embodiments, the Aβ-binding region comprises a Fab region of an anti-Aβ antibody, two Fab regions of an anti-Aβ antibody, an F(ab)2 region of an anti-Aβ antibody, or at least one scFv derived from an anti-Aβ antibody. In some embodiments, the Aβ-binding region comprises an antigen-binding domain of aducanumab. In some embodiments, the Aβ-binding region comprises a Fab region of aducanumab, two Fab regions of aducanumab, an F(ab)2 region of aducanumab, or at least one scFv derived from aducanumab.

[0091] In some implementations, the Aβ binding region comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein

[0092] (a) The VH comprises a first heavy chain complementarity-determining region (VHCDR1) having the amino acid sequence of SEQ ID NO:1, a second heavy chain complementarity-determining region (VHCDR2) having the amino acid sequence of SEQ ID NO:2, and a third heavy chain complementarity-determining region (VHCDR3) having the amino acid sequence of SEQ ID NO:3; and

[0093] (b) The VL comprises a first light chain complementarity-determining region (VLCDR1) having the amino acid sequence of SEQ ID NO:4, a second light chain complementarity-determining region (VLCDR2) having the amino acid sequence of SEQ ID NO:5, and a third light chain complementarity-determining region (VLCDR3) having the amino acid sequence of SEQ ID NO:6.

[0094] VH and VL can be part of Fab, F(ab)2, or scFv.

[0095] In some implementations, the Aβ binding region comprises VH and VL, wherein

[0096] (a) VH comprises an amino acid sequence having at least 85%, at least 90%, or at least 95% identity with amino acids 1-120 of SEQ ID NO:8 or 10, and wherein VH comprises VHCDR1 having the amino acid sequence of SEQ ID NO:1, VHCDR2 having the amino acid sequence of SEQ ID NO:2, and VHCDR3 having the amino acid sequence of SEQ ID NO:3; and

[0097] (b) VL comprises an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to amino acids 1-109 of SEQ ID NO:7, and wherein VL comprises VLCDR1 having the amino acid sequence of SEQ ID NO:4, VLCDR2 having the amino acid sequence of SEQ ID NO:5, and VLCDR3 having the amino acid sequence of SEQ ID NO:6.

[0098] VH and VL can be part of Fab, F(ab)2, or scFv.

[0099] In some embodiments, the Aβ binding region comprises VH and VL, wherein VH comprises the amino acid sequence of amino acids 1-120 of SEQ ID NO:8 or 10 and VL comprises amino acids 1-109 of SEQ ID NO:7. VH and VL may be part of Fab, F(ab)2, or scFv.

[0100] In some implementations, the Aβ binding region comprises a heavy chain Fab region and a light chain Fab region, wherein

[0101] (a) The heavy chain Fab region contains an amino acid sequence having at least 85%, at least 90%, or at least 95% identity with amino acids 1-227 of SEQ ID NO: 8 or 10, and contains VHCDR1 having the amino acid sequence of SEQ ID NO: 1, VHCDR2 having the amino acid sequence of SEQ ID NO: 2, and VHCDR3 having the amino acid sequence of SEQ ID NO: 3.

[0102] (b) The light chain Fab region contains an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to SEQ ID NO:7 and contains VLCDR1 having the amino acid sequence of SEQ ID NO:4, VLCDR2 having the amino acid sequence of SEQ ID NO:5, and VLCDR3 having the amino acid sequence of SEQ ID NO:6.

[0103] In some implementations, the Aβ binding region comprises an F(ab)2 region having two heavy-chain Fab regions and two light-chain Fab regions, wherein

[0104] (a) Each heavy chain Fab region contains an amino acid sequence having at least 85%, at least 90%, or at least 95% identity with amino acids 1-227 of SEQ ID NO: 8 or 10, and contains VHCDR1 having the amino acid sequence of SEQ ID NO: 1, VHCDR2 having the amino acid sequence of SEQ ID NO: 2, and VHCDR3 having the amino acid sequence of SEQ ID NO: 3.

[0105] (b) Each light chain Fab region contains an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to SEQ ID NO:7 and contains VLCDR1 having the amino acid sequence of SEQ ID NO:4, VLCDR2 having the amino acid sequence of SEQ ID NO:5, and VLCDR3 having the amino acid sequence of SEQ ID NO:6.

[0106] In some embodiments, the Aβ binding region comprises a heavy chain Fab region and a light chain Fab region, wherein the heavy chain Fab region comprises the amino acid sequence of amino acids 1-227 of SEQ ID NO:8 or 10, and the light chain Fab region comprises the amino acid sequence of SEQ ID NO:7.

[0107] In some embodiments, the Aβ binding region comprises an F(ab)2 region having two heavy chain Fab regions and two light chain Fab regions, wherein each heavy chain Fab region contains the amino acid sequence of amino acids 1-227 of SEQ ID NO:8 or 10 and each light chain Fab region contains the amino acid sequence of SEQ ID NO:7.

[0108] B. Transferrin receptor (TfR) binding domain

[0109] A TfR binding region is a region or domain of a molecule, such as a polypeptide or larger polypeptide or protein, that specifically binds to a TfR (such as human TfR). The TfR binding region of an Aβ-targeting protein specifically binds to a TfR and facilitates the transport of the Aβ-targeting protein across the blood-brain barrier (e.g., via receptor-mediated transcytosis) or increases the penetration of the Aβ-targeting protein into the brain.

[0110] The transferrin receptor (TfR) (also known as differentiation cluster 71 (CD71)) binds to transferrin (Tf) and plays a crucial role in cellular iron uptake through interactions with iron-bound transferrin. TfR is highly expressed by brain capillary endothelial cells (BCECs), which form the blood-brain barrier (BBB). TfR is a 90 kDa type II transmembrane glycoprotein composed of 760 amino acids, found to be a 180 kDa dimer linked by disulfide bonds on the cell surface. The TfR1 monomer consists of a large extracellular C-terminal domain (671 amino acids) containing a Tf binding site, a transmembrane domain (28 amino acids), and an intracellular N-terminal domain (61 amino acids). The C-terminal extracellular domain contains three N-linked glycosylation sites at asparagine residues 251, 317, and 727 and one O-linked glycosylation site at threonine 104; these sites are essential for the receptor's full function.

[0111] In some embodiments, the TfR binding region binds to the apical domain of TfR. The apical domain contains residues 189-383 of TfR. In some embodiments, the TfR binding region binds to an epitope at position 208, which contains the full-length human transferrin receptor sequence. In some embodiments, the TfR binding region binds to the apical domain of TfR at epitopes at positions 158, 188, 199, 207, 208, 209, 210, 211, 212, 213, 214, 215, and / or 294, which contain the full-length human TfR sequence (SEQ ID NO: 15).

[0112] In some embodiments, the binding of the TfR binding region to TfR does not inhibit the binding of transferrin to TfR. In some embodiments, the binding of the Aβ-targeting protein to TfR does not inhibit the binding of transferrin to TfR. In some embodiments, the binding of transferrin to TfR is inhibited by less than about 50% (e.g., less than about 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%). In some embodiments, the binding of transferrin to TfR is inhibited by less than about 20% (e.g., less than about 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%).

[0113] In some embodiments, the TfR binding region specifically binds to human TfR with an affinity of about 900 nM to about 10,000 nM. In some embodiments, the TfR binding region specifically binds to human TfR with an affinity of about 900 nM to about 8500 nM. In some embodiments, the TfR binding region specifically binds to human TfR with an affinity of about 900 nM to about 6500 nM. In some embodiments, the TfR binding region specifically binds to human TfR with an affinity of about 900 nM to about 5000 nM. In some embodiments, the TfR binding region specifically binds to human TfR with an affinity of about 900 nM to about 3500 nM. In some embodiments, the TfR binding region specifically binds to human TfR with an affinity of about 900 nM to about 2500 nM. In some embodiments, the TfR binding region specifically binds to human TfR with an affinity of about 900 nM to about 2000 nM. In some embodiments, the TfR binding region specifically binds to human TfR with an affinity of about 900 nM to about 1600 nM. In some embodiments, the TfR binding region specifically binds to human TfR with an affinity of about 900 nM to about 1300 nM. In some embodiments, the TfR binding region specifically binds to human TfR with an affinity of about 1000 nM to about 1200 nM. In some implementations, the TfR binding region specifically binds to human TfR with an affinity of about 1400 nM, about 1500 nM, about 1600 nM, about 1800 nM, about 2000 nM, about 2500 nM, about 3000 nM, about 3500 nM, about 4000 nM, about 4500 nM, about 5000 nM, about 5500 nM, about 6000 nM, about 6500 nM, about 7000 nM, about 7500 nM, about 8000 nM, about 8500 nM, about 9000 nM, or about 10,000 nM. In some embodiments, the TfR binding region specifically binds to human TfR with an affinity of about 900 nM, about 950 nM, about 1000 nM, about 1050 nM, about 1100 nM, about 1150 nM, or about 1200 nM. In some embodiments, the TfR binding region specifically binds to human TfR with an affinity of 1100 ± 200 nM. In some embodiments, the TfR binding region specifically binds to human TfR with an affinity of 1100 ± 100 nM. In some embodiments, the TfR binding region specifically binds to human TfR with an affinity of 1100 ± 50 nM. In some embodiments, the TfR binding region specifically binds to human TfR with an affinity of 1100 nM.

[0114] In some embodiments, the Aβ-targeting protein specifically binds to human TfR with an affinity of about 900 nM to about 10,000 nM. In some embodiments, the TfR-binding region specifically binds to human TfR with an affinity of about 900 nM to about 8500 nM. In some embodiments, the Aβ-targeting protein specifically binds to human TfR with an affinity of about 900 nM to about 6500 nM. In some embodiments, the Aβ-targeting protein specifically binds to human TfR with an affinity of about 900 nM to about 5000 nM. In some embodiments, the Aβ-targeting protein specifically binds to human TfR with an affinity of about 900 nM to about 3500 nM. In some embodiments, the Aβ-targeting protein specifically binds to human TfR with an affinity of about 900 nM to about 2500 nM. In some embodiments, the Aβ-targeting protein specifically binds to human TfR with an affinity of about 900 nM to about 2000 nM. In some embodiments, the Aβ-targeting protein specifically binds to human TfR with an affinity of about 900 nM to about 1600 nM. In some embodiments, the Aβ-targeting protein specifically binds to human TfR with an affinity of about 900 nM to about 1300 nM. In some embodiments, the Aβ-targeting protein specifically binds to human TfR with an affinity of about 1400 nM, about 1500 nM, about 1600 nM, about 1800 nM, about 2000 nM, about 2500 nM, about 3000 nM, about 3500 nM, about 4000 nM, about 4500 nM, about 5000 nM, about 5500 nM, about 6000 nM, about 6500 nM, about 7000 nM, about 7500 nM, about 8000 nM, about 8500 nM, about 9000 nM, or about 10,000 nM. In some embodiments, the Aβ-targeting protein specifically binds to human TfR with an affinity of about 1000 nM to about 1200 nM. In some embodiments, the Aβ-targeting protein specifically binds to human TfR with an affinity of about 900 nM, about 950 nM, about 1000 nM, about 1050 nM, about 1100 nM, about 1150 nM, or about 1200 nM. In some embodiments, the Aβ-targeting protein specifically binds to human TfR with an affinity of 1100 ± 200 nM. In some embodiments, the Aβ-targeting protein specifically binds to human TfR with an affinity of 1100 ± 100 nM. In some embodiments, the Aβ-targeting protein specifically binds to human TfR with an affinity of 1100 ± 50 nM. In some embodiments, the Aβ-targeting protein specifically binds to human TfR with an affinity of 1100 nM.

[0115] Analyzing the binding affinity, binding kinetics, and cross-reactivity between the TfR binding region and TfR can be performed using methods available in the art for analyzing the binding affinity, binding kinetics, and cross-reactivity between two peptides. These methods include, but are not limited to, solid-state binding assays (e.g., ELISA), immunoprecipitation, and surface plasmon resonance (e.g., Biacore) assays. TM (GE Healthcare, Piscataway, NJ)), kinetic exclusion assays (e.g.) ), flow cytometry, fluorescence activated cell sorting (FACS), BioLayer interferometry (e.g.) (ForteBio, Inc., Menlo Park, CA) and Western blot analysis. In some embodiments, ELISA is used to determine binding affinity and / or cross-reactivity. Methods for performing ELISA assays are known in the art. In some embodiments, surface plasmon resonance (SPR) is used to determine binding affinity, binding kinetics, and / or cross-reactivity. In some embodiments, kinetic exclusion assays are used to determine binding affinity, binding kinetics, and / or cross-reactivity. In some embodiments, BioLayer interferometry assays are used to determine binding affinity, binding kinetics, and / or cross-reactivity. In some embodiments, surface plasmon resonance (optionally using Biacore) is used to determine binding affinity, binding kinetics, and / or cross-reactivity. TM The binding affinity is determined using an instrument. In this method, the TfR-binding peptide is captured on a sensor chip, and a serially diluted solution of TfR is injected onto the sensor chip at a specified flow rate (e.g., 30 μL / min) and temperature (e.g., room temperature). The sample is analyzed using specified association and dissociation times (e.g., 45 seconds and 180 seconds, respectively), followed by sensor chip regeneration. The binding reaction is corrected by subtracting the measured reaction from a control (e.g., using unrelated IgG of similar density), and steady-state affinity is then determined by fitting an equilibrium reaction for concentration using software.

[0116] In some implementations, the Aβ-targeting protein is monovalent to the TfR-binding region, meaning that the Aβ-targeting protein contains a single TfR-binding region.

[0117] The TfR binding region can be, but is not limited to, a peptide, an engineered peptide, an anti-TfR antibody, a TfR binding fragment of an anti-TfR antibody, or a region of an antibody modified to bind to human TfR.

[0118] Anti-TfR antibodies are known in the art and are available from various commercial sources. Anti-TfR may be an antibody against TfR from a non-human species, provided that the antibody binds to human TfR with the affinity described above (e.g., from about 900 nM to about 10,000 nM). In some embodiments, the anti-TfR antibody or its TfR-binding fragment binds to the apical domain of the TfR. In some embodiments, the binding of the anti-TfR antibody or its TfR-binding fragment to the TfR does not inhibit the binding of transferrin to the TfR. Exemplary anti-TfR antibodies include, but are not limited to, B3 / 25, RBC4, 7579, E2.3, A27.15, D65.30, D2C, ch128.1Av, ch128.1 / IgG3, ch128.1 / IgG1, hu128.1 (Candelaria et al. Front. Immunol. 12 (March 17, 2021), 2021), Ri7, and 8D3 (Weber et al., Cell Reports 22:149-162, 2018). Exemplary anti-TfR antibodies are also described in the following U.S. patent publications: US2018282408A1, US2020071413A1, US20210138083, US20190092870, and US20130028891. Anti-TfR antibodies can be modified to have an affinity for TfR of about 900 nM to about 10,000 nM.

[0119] The TfR binding fragment of an anti-hTfR antibody can be, but is not limited to, a Fab fragment or a single-chain variable fragment (scFv), or a monovalent anti-TfR antibody, or a bivalent antibody with a single TfR binding domain.

[0120] In some embodiments, the TfR binding region includes the antigen-binding domain of the anti-TfR antibody. In some embodiments, the TfR binding region includes the Fab region of the anti-TfR antibody or an scFv derived from the anti-TfR antibody.

[0121] The TfR binding region can be derived from proteins known to bind TfR, such as reticulocyte-binding protein 2b (PvRBP2b) from Plasmodium vivax, or viral proteins known to bind TfR, such as arenavirus proteins (e.g., Machupo, Sabiá, Junín, Guanarito, or Chapare viruses).

[0122] In some embodiments, the TfR binding region comprises an engineered peptide. The engineered peptide can be a peptide (e.g., an antibody Fc peptide) or an antigen-binding region of an anti-TfR antibody, modified to alter the affinity of the peptide or the antigen-binding region of the anti-TfR antibody for Tfr. Engineered peptides can be identified or generated using methods in the art for identifying or generating peptides with affinity for known targets (e.g., TfR). Such methods include, but are not limited to, phage display, yeast display (e.g., yeast surface display), and directed evolution and combinations thereof.

[0123] A method for engineering the CH2 or CH3 domain to enable transferrin receptor binding has been previously described in U.S. Patent Publication US20200223935 (incorporated herein by reference). The nucleic acid encoding a polypeptide (e.g., the CH2 or CH3 domain) can be modified to encode 1-10 or more amino acid mutations. The encoded modification may occur at a predetermined site, may occur randomly within a selected predetermined site, or may occur randomly. The encoded modification may be random, partially random, or deviated from the amino acid drug. The encoded modified polypeptide is then expressed using any number of systems (e.g., display systems). Display systems may be, but are not limited to, viral display systems, cell surface display systems (such as yeast display systems), mRNA display systems, or polyribosome display systems. The modified polypeptide is then screened using known methods to identify transferrin receptor binders, which may be further characterized to determine binding affinity. Polypeptides identified as having affinity for TfR may undergo one or more rounds of additional mutation, expression, display, and selection until a polypeptide with the desired affinity for TfR is identified.

[0124] In some embodiments, the engineered peptide comprises an antibody Fc peptide modified to bind transferrin. The Fc peptide modified to bind TfR may comprise a CH2 domain modified to bind TfR or a CH3 domain modified to bind TfR. The CH2 or CH3 domain modified to bind TfR may be derived from IgG1, IgG2, IgG3, or IgG4. In some embodiments, the TfR binding region comprises a CH3 domain derived from IgG1 modified to bind transferrin. In some embodiments, the TfR binding region comprises a CH3 domain derived from IgG1 modified to bind transferrin with an affinity of about 900 nM to about 10,000 nM (e.g., about 900 nM to about 2500 nM or about 900 nM to about 1300 nM).

[0125] In some embodiments, the engineered peptide comprises an antibody CH2 domain modified to bind TfR or an antibody CH3 domain modified to bind TfR. The CH2 or CH3 domain modified to bind TfR may be derived from IgG1, IgG2, IgG3, or IgG4. In some embodiments, the TfR-binding region comprises a CH3 domain derived from IgG1 modified to bind transferrin. In some embodiments, the TfR-binding region comprises a CH3 domain derived from IgG1 modified to bind transferrin with an affinity of about 900 nM to about 10,000 nM (e.g., about 900 nM to about 2500 nM or about 900 nM to about 1300 nM). The CH3 domains of other immunoglobulin isotypes (e.g., IgM, IgA, IgE, IgD, etc.) can be similarly modified by identifying amino acids in those domains corresponding to the amino acid positions described herein. It can also modify the corresponding domains of immunoglobulins from other species (such as non-human primates, monkeys, mice, rats, rabbits, dogs, pigs, chickens, etc.).

[0126] In some embodiments, the TfR binding region comprises a modified CH3 domain having, according to the EU numbering scheme, at least six, seven, eight, nine, or ten amino acid substitutions selected from the following positions: 380, 384, 386, 387, 388, 398, 390, 413, 415, 416, and 421. In some embodiments, the TfR binding region comprises a modified CH3 domain having, according to the EU numbering scheme, tyrosine or phenylalanine at position 384, threonine or asparagine at position 386, aspartic acid at position 387, tryptophan at position 388, serine, threonine, or valine at position 389, serine or asparagine at position 390, threonine or serine at position 413, serine or glutamine at position 415, glutamic acid at position 416, and phenylalanine or tyrosine at position 421. In some embodiments, the TfR binding region comprises a modified CH3 domain having tyrosine (Y) at position 384, threonine (T) at position 386, glutamic acid (E) at position 387, tryptophan (W) at position 388, valine (V) at position 389, threonine (T) at position 413, glutamic acid (E) at position 415, glutamic acid (E) at position 416, and phenylalanine (F) at position 421 (according to the EU numbering scheme).

[0127] In some embodiments, the TfR binding region comprises a modified CH3 domain having substitutions from any of the groups listed in Table 1. In some embodiments, the TfR binding region comprises a modified CH3 domain having substitutions from any of the groups listed in Table 1 and having an amino acid sequence of at least 85%, at least 90%, or at least 95% identity with amino acids 348-454 (according to the EU numbering scheme) of any of SEQ ID NO:8, 10, and 17-31.

[0128] Table 1. Amino acid substitutions in the Fc domain of IgG that lead to TfR binding. Amino acid positions are based on the EU numbering scheme. Wild-type amino acids are shown for reference.

[0129]

[0130] In some embodiments, the TfR binding region comprises a modified CH3 domain polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 348-454 of SEQ ID NO: 8 or 10, wherein the polypeptide has Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme).

[0131] In some embodiments, the TfR binding region comprises the amino acid sequence of amino acids 348-453 or 348-454 of any of SEQ ID NO:8, 10, or 17-31.

[0132] In some embodiments, the TfR binding region comprises a modified Fc polypeptide having an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% homology with amino acid 228-454 of any of SEQ ID NO: 8, 10, or 17-31, wherein the polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1. In some embodiments, the TfR binding region comprises a modified Fc polypeptide having an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99% similarity to amino acids 228-454 of SEQ ID NO: 8 or 10, wherein the polypeptide has Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme).

[0133] In some embodiments, the TfR binding region comprises a modified Fc polypeptide having an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99% homology with amino acids 228-454 of SEQ ID NO: 8 or 10, wherein the polypeptide has A at position 234, A at position 235, G optionally at position 239, Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme).

[0134] In some embodiments, the TfR binding region comprises the amino acid sequence of amino acids 228-453 or 228-454 of any of SEQ ID NO:8, 10, and 17-31.

[0135] C.Fcγ receptor (FcγR) binding domain

[0136] The FcγR binding region contains a polypeptide, region, domain, or protein that specifically binds to FcγR and is capable of inducing effector functional activity. Effector functions include, but are not limited to, ADCP, ADCC, and CDC. Effector functions are typically mediated by the binding of FcγR to the Fc domain of immunoglobulins such as IgG. The described Aβ-targeting protein can mediate at least one effector function. The effector function can help clear amyloid plaques in the brain of a subject. In some embodiments, the described Aβ-targeting protein is configured such that the binding of the Aβ-targeting protein to TfR reduces the binding of the FcγR binding region to FcγR. In some embodiments, the described Aβ-targeting protein mediates the effector function when bound to Aβ (binding FcγR), but does not mediate the effector function or the effectiveness of mediating the effector function is reduced when bound to TfR (not binding FcγR or reduced binding to FcγR).

[0137] Fc receptors are proteins visible on the surface of immune cells that contribute to the protective function of the immune system. Fc-γ receptors (FcγR) recognize IgG-coated targets, such as opsonized antigens or immune complexes (ICs). FcγR induces antibody-mediated phagocytosis (ADCP), antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).

[0138] The FcγR binding region may comprise an Fc polypeptide derived from an immunoglobulin. The Fc polypeptide may comprise all or a portion of the CH2 and CH3 domains of the immunoglobulin heavy chain. In some embodiments, the FcγR binding region comprises an Fc polypeptide derived from IgG1, IgG2, IgG3, or IgG4, such as human IgG1, IgG2, IgG3, or IgG4. The Fc polypeptide may comprise all or a portion of the CH2 and CH3 domains of the immunoglobulin heavy chain. Many mutations (e.g., substitution, deletion, or insertion) are known in the art for increasing or decreasing the binding of the Fc polypeptide to FcγR. In some embodiments, the FcγR binding region comprises an Fc polypeptide without any mutations that decrease FcγR binding. The FcγR binding region may comprise an Fc polypeptide with one or more mutations that increase FcγR binding or enhance effector function.

[0139] In some embodiments, the FcγR binding region comprises approximately 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the wild-type Fc peptide (e.g., human IgG1, IgG2, IgG3, or IgG4 Fc peptide).

[0140] In some embodiments, the FcγR binding region comprises an Fc polypeptide and does not contain a TfR binding site, the Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homology with amino acids 228-454 of SEQ ID NO:9.

[0141] In some embodiments, the FcγR binding region comprises an Fc polypeptide and contains no TfR binding site or any modification that reduces FcγR binding, the Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homology with amino acids 228-454 of SEQ ID NO:9.

[0142] In some embodiments, the FcγR binding region comprises an Fc polypeptide having an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homology with amino acids 228-454 of SEQ ID NO:9, having S at position 366, A at position 368, and V at position 407, and containing no TfR binding site or any modifications that reduce FcγR binding.

[0143] In some embodiments, the FcγR binding region comprises an Fc polypeptide containing an amino acid sequence that is 100% identical to amino acids 228-453 or 228-454 of SEQ ID NO:9.

[0144] Methods for analyzing the binding affinity, binding kinetics, and cross-reactivity between the FcγR binding region and FcγR are known in the art. These methods include, but are not limited to, solid-state binding assays (e.g., ELISA assays), immunoprecipitation, and surface plasmon resonance (e.g., Biacore) assays. TM (GE Healthcare, Piscataway, NJ)), kinetic exclusion assays (e.g.) ), flow cytometry, fluorescence activated cell sorting (FACS), BioLayer interferometry (e.g.) (ForteBio, Inc., Menlo Park, CA) and Western blot analysis. In some embodiments, ELISA is used to determine binding affinity and / or cross-reactivity. Methods for performing ELISA assays are known in the art. In some embodiments, surface plasmon resonance (SPR) is used to determine binding affinity, binding kinetics, and / or cross-reactivity. In some embodiments, kinetic exclusion assays are used to determine binding affinity, binding kinetics, and / or cross-reactivity. In some embodiments, BioLayer interferometry assays are used to determine binding affinity, binding kinetics, and / or cross-reactivity.

[0145] Modifications may need to be introduced into Fc peptides containing the FcγR binding region to enhance effector function. One method for enhancing effector function involves generating Fc peptides with no fucosylation or fucosylation-deficient modifications. One method for generating fucosyl-deficient Fc peptides is to use fucosyl analogs, such as 2-fluorofucosyl (2-FF). Fucosyl analogs deplete or reduce the availability of GDP-fucosyl, a substrate required by fucosyltransferases to incorporate fucosyl into proteins. An alternative method for generating fucosyl-deficient Fc peptides is to express the Fc peptide using an α-1,6-fucosyltransferase (FUT8) knockout cell line. A non-limiting example of a suitable FUT8 knockout cell line is the Chinese hamster ovary (CHO) FUT8 knockout cell line available from LonzaBiologies. In addition, as described by Mori et al. (Biotechnol. Bioeng. (2004) 88: 901-908; all of which are hereby incorporated by reference), FUT8 small interfering RNA (siRNA) can be used to transform CHO cell lines (e.g., through constitutive expression of FUT8 siRNA) to produce fucose-deficient proteins.

[0146] D.Fc dimer

[0147] In some embodiments, the TfR binding region and the Fcγ binding region are provided by an Fc dimer polypeptide. The TfR binding function and the FcγR binding function can be provided on a modified Fc dimer, wherein the Fc dimer comprises a first Fc polypeptide and a second Fc polypeptide. In some embodiments, the TfR binding region is provided on the first Fc polypeptide and the FcγR binding region is provided on both the first and second Fc polypeptides. In some embodiments, both the TfR binding region and the FcγR binding region are provided on the first Fc polypeptide. In some embodiments, the TfR binding region is provided on the first Fc polypeptide and the FcγR binding region is provided on the second Fc polypeptide.

[0148] In some embodiments, the first Fc polypeptide contains a TfR binding region and does not contain any mutations that weaken effector functions (e.g., FcγR binding, ADPC, ADCC, or CDC).

[0149] In some embodiments, the first Fc polypeptide includes a TfR-binding region and a mutation in one or more attenuating effector functions (e.g., FcγR binding, ADPC, ADCC, or CDC). In some embodiments, the first Fc polypeptide includes a CH3 domain modified to bind to the TfR-binding region and a mutation in one or more attenuating effector functions.

[0150] An Fc polypeptide with "reduced binding to FcγR" refers to an Fc polypeptide containing a mutated modification in the CH2 and / or CH3 domains, which results in a reduced affinity of the Fc polypeptide for FcγR. The affinity of an Fc polypeptide with reduced binding to FcγR for FcγR can be reduced by about 10% to about 90% compared to a wild-type Fc polypeptide or an Fc polypeptide without the mutated reduction in FcγR binding. In some embodiments, the mutated reduction in FcγR binding or attenuation of effector function reduces FcγR binding or attenuation of effector function by about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 35% or more, about 40% or more, about 45% or more, about 50% or more, 55% or more, about 60% or more, about 65% or more, about 70% or more, about 75% or more, about 80% or more, about 85% or more, or about 90% or more. FcγR binding can be achieved using methods such as surface plasmon resonance (SPR) (e.g., Biacore). TM The system can be used to measure FcγR binding. Alternatively, functional assays, such as ADCP or ADCC assays (e.g., in vivo or in vitro assays for cell killing), can be used to measure FcγR binding. The reduction in FcγR binding can be measured when the modified Fc peptide, Fc dimer, or Aβ-targeting protein binds to TfR and / or Aβ. In some embodiments, the reduction in FcγR binding when the Fc peptide, Fc dimer, or Aβ-targeting protein is bound to TfR may be greater than when it is not bound to TfR.

[0151] In some implementations, the second Fc peptide does not contain a TfR binding region and does not contain any modifications that reduce FcγR binding.

[0152] In some embodiments, the Fc dimer comprises a first Fc peptide containing a CH3 domain and a CH2 domain modified to bind TfR, wherein the CH2 domain is free of any mutations that attenuate the effector function; and a second Fc peptide containing a CH3 domain and a CH2 domain, wherein the second Fc peptide is free of the TfR binding region.

[0153] In some embodiments, the Fc dimer comprises a first Fc peptide containing a CH3 and CH2 domain modified to bind TfR, wherein the CH2 domain is free from any mutations that attenuate the effector function; and a second Fc peptide containing a CH3 and CH2 domain, wherein the second Fc peptide is free from the TfR binding region and free from any modifications that reduce FcγR binding.

[0154] In some embodiments, the Fc dimer comprises a first Fc peptide comprising a CH3 domain and a CH2 domain modified to bind TfR, wherein the CH2 domain does not contain any mutations that attenuate the effector function; and a second Fc peptide comprising a CH3 domain and a CH2 domain, wherein the second Fc peptide does not contain a TfR binding region and wherein the CH2 domain contains one or more mutations that attenuate the effector function.

[0155] In some embodiments, the first Fc peptide comprises a CH3 domain modified to bind a TfR-binding region and one or more mutations that attenuate effector function, and the second Fc peptide does not contain any modifications that attenuate effector function (e.g., FcγR binding). In some embodiments, the Fc dimer comprises a first Fc peptide comprising a CH3 domain modified to bind TfR and a CH2 domain modified to attenuate effector function (e.g., FcγR binding, ADPC, ADCC, or CDC); and a second Fc peptide comprising the CH3 and CH2 domains, wherein the second Fc peptide does not contain a TfR-binding region and does not contain any modifications that reduce FcγR binding. Antibody constructs having this Fc dimer conformation are described in WO2019140050. Aβ-targeting proteins having this Fc dimer conformation do not bind FcγR or mediate effector function when bound to TfR, or have reduced FcγR binding or attenuated effector function, but are able to bind FcγR and mediate effector function when not bound to TfR. Reduced binding to FcγR and weakened effector function when bound to TfR leads to decreased reticulocyte depletion. This dimer also provides effector function when the Aβ-targeting protein binds to Aβ. When bound to Aβ, effector functions (e.g., amyloid plaques or fibrils) can promote a reduction in amyloid plaques or fibrils in subjects.

[0156] In some embodiments, the described Aβ-targeting protein does not cause a significant reduction in reticulocytes (e.g., a reduction in bone marrow reticulocytes or circulating reticulocytes). In some embodiments, administration of the described Aβ-targeting protein to a subject causes a reduction in bone marrow or circulating reticulocytes of less than 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 8%, 5%, 3%, 2%, or 1% compared to the number of bone marrow or circulating reticulocytes in the subject before administration of the Aβ-targeting protein, compared to a control subject receiving a control protein, or compared to a predetermined control.

[0157] Mutations in Fc peptides that regulate effector function include, but are not limited to, substitutions at the following positions: 234 (e.g., L234A), 235 (e.g., L235A), and 329 (e.g., P329G) (IgG1 Fc); 228 (e.g., S228P) and 235 (e.g., L235E) (IgG4 Fc); 234 (e.g., L234A) and 237 (e.g., G237A) (IgG1 Fc); 234 (e.g., L234A), 235 (e.g., L235A), and 237 (e.g., G237A) (IgG1 Fc); 234 (e.g., V234A) and 237 (e.g., G237A) (IgG2 Fc); 235 (e.g., L235A), 237 (e.g., G237A), and 318 (e.g., E318A) (IgG4 Fc). Fc); and 228 (e.g., S228P) and 236 (e.g., L236E) (IgG4 Fc) (according to the EU numbering scheme).

[0158] In some embodiments, the first Fc polypeptide comprises one or more of L234A, L235A, or P329G substitutions. In some embodiments, the first Fc polypeptide comprises L234A and L235A substitutions. In some embodiments, the first Fc polypeptide comprises P329G substitution. In some embodiments, the first Fc polypeptide comprises L234A, L235A, and P329G substitutions.

[0159] In some embodiments, the Fc dimer comprises: (a) a first Fc polypeptide containing a TfR binding region and amino acid modifications L234A and L235A (according to the EU numbering scheme), and (b) a second Fc polypeptide that does not contain a TfR binding site or any modifications that reduce FcγR binding.

[0160] In some embodiments, the Fc dimer comprises: (a) a first Fc polypeptide containing a TfR binding region and amino acid modifications L234A, L235A and P329G (according to the EU numbering scheme), and (b) a second Fc polypeptide that does not contain a TfR binding site or any modifications that reduce FcγR binding.

[0161] Fc dimers may be provided as a single chain or as two polypeptides. The first or second Fc polypeptide in the Fc dimer may have one or more mutations that promote heterodimerization of the two Fc polypeptides. Any Fc mutation known in the art that promotes, facilitates, or enhances heterodimerization may be used with the described Fc polypeptide. Such mutations include, but are not limited to, club-and-mortar mutations. In some embodiments, the first Fc polypeptide contains a club mutation and the second Fc polypeptide contains a mortar mutation. The club mutation may contain a T366W substitution (according to the EU numbering scheme). The mortar mutation may contain T366S, T368A, and Y407V substitutions (according to the EU numbering scheme). In some embodiments, the first Fc polypeptide contains a T366W substitution, and the second Fc polypeptide contains T366S, T368A, and Y407V substitutions. In some embodiments, the first Fc polypeptide comprises T366S, T368A, and Y407V substitutions, and the second Fc polypeptide comprises T366W substitution.

[0162] In some embodiments, the Fc dimer comprises: (a) a first Fc polypeptide containing a TfR binding site that specifically binds to TfR, amino acid modifications L234A and L235A, and mortar mutations T366S, L368A, and Y407V (according to the EU numbering scheme), and (b) a second Fc polypeptide containing a mortar mutation T366W (according to the EU numbering scheme) and containing no TfR binding site or any modifications that reduce FcγR binding.

[0163] In some embodiments, the Fc dimer comprises: (a) a first Fc polypeptide containing a TfR binding site that specifically binds to TfR, amino acid modifications L234A, L235A and P329G, and mortar mutations T366S, L368A and Y407V (according to the EU numbering scheme), and (b) a second Fc polypeptide containing a mortar mutation T366W (according to the EU numbering scheme) and containing no TfR binding site or any modifications that reduce FcγR binding.

[0164] In some embodiments, the Fc dimer comprises: (a) a first Fc polypeptide containing a TfR binding site that specifically binds to TfR, amino acid modifications L234A and L235A, and a mortar mutation T366W (according to the EU numbering scheme), and (b) a second Fc polypeptide containing mortar mutations T366S, L368A, and Y407V (according to the EU numbering scheme), and without a TfR binding site or any modifications that reduce FcγR binding.

[0165] In some embodiments, the Fc dimer comprises: (a) a first Fc polypeptide containing a TfR binding site that specifically binds to TfR, amino acid modifications L234A, L235A and P329G, and a mortar mutation T366W (according to the EU numbering scheme), and (b) a second Fc polypeptide containing mortar mutations T366S, L368A and Y407V (according to the EU numbering scheme), and without a TfR binding site or any modifications that reduce FcγR binding.

[0166] In some embodiments, the Fc dimer comprises (a) a first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homology with amino acid 228-454 of any of SEQ ID NO: 8, 10, and 17-31, wherein the polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1; and (b) a second Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homology with amino acid 228-454 of any of SEQ ID NO: 8, 10, and 17-3 ...c) an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homology with amino acid 228-454 of any of SEQ ID NO: 8, 10, and 17-31; and (d) an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homology with amino acid 228-454 of any of SEQ ID NO: 8, 10, and 17-3 The amino acid sequence of NO:9, 228-454, has at least 70% or at least 75% or at least 80% or at least 85% or at least 90% homology, wherein the second Fc polypeptide has S and V at positions 366, A and 368 and 407, and contains no TfR binding sites or any modifications that reduce FcγR binding.

[0167] In some embodiments, the Fc dimer comprises: a first Fc polypeptide comprising an amino acid sequence having 100% identity with amino acid 225-453 or 228-454 of any one of SEQ ID NO:8, 10, and 17-31; and a second Fc polypeptide comprising an amino acid sequence having 100% identity with amino acid 228-453 or 228-454 of SEQ ID NO:9. In some embodiments, the Fc dimer comprises: a first Fc polypeptide comprising an amino acid sequence having 100% identity with amino acid 228-453 of SEQ ID NO:8, 10, and 17-31; and a second Fc polypeptide comprising an amino acid sequence having 100% identity with amino acid 228-453 of SEQ ID NO:9. In some embodiments, the first Fc polypeptide comprises: (a) A at position 234 and A at position 235, (b) G at position 329, (c) A at position 234, A at position 235 and G at position 329, (d) W at position 366, (e) A at position 234, A at position 235 and W at position 366, (f) G at position 329 and W at position 366, or (g) A at position 234 and A at position 235, G at position 329 and W at position 366.

[0168] In some embodiments, the Fc dimer comprises: (a) a first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 228-454 of SEQ ID NO:8, wherein the first Fc polypeptide comprises A at position 234 and A at position 235, G at position 329, W at position 366, Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme); and (b) a second Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 228-454 of SEQ ID NO:8. The amino acid sequence of NO:9, 228-454, has at least 70% or at least 75% or at least 80% or at least 85% or at least 90% homology, wherein the second Fc polypeptide has S and V at positions 366, A and 368 and 407, and contains no TfR binding sites or any modifications that reduce FcγR binding.

[0169] In some embodiments, the Fc dimer comprises: a first Fc polypeptide comprising an amino acid sequence that is 100% identical to amino acids 228-454 of SEQ ID NO:8; and a second Fc polypeptide comprising an amino acid sequence that is 100% identical to amino acids 228-454 of SEQ ID NO:9. In some embodiments, the Fc dimer comprises: a first Fc polypeptide comprising an amino acid sequence that is 100% identical to amino acids 228-453 of SEQ ID NO:8; and a second Fc polypeptide comprising an amino acid sequence that is 100% identical to amino acids 228-453 of SEQ ID NO:9.

[0170] In some embodiments, the Fc dimer comprises: (a) a first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 228-454 of SEQ ID NO:10, wherein the first Fc polypeptide has A at position 234 and A at position 235, W at position 366, Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme); and (b) a second Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 228-454 of SEQ ID NO:10. The amino acid sequence of NO:9, 228-454, has at least 70% or at least 75% or at least 80% or at least 85% or at least 90% homology, wherein the second Fc polypeptide has S and V at positions 366, A and 368 and 407, and contains no TfR binding sites or any modifications that reduce FcγR binding.

[0171] In some embodiments, the Fc dimer comprises: a first Fc polypeptide comprising an amino acid sequence that is 100% identical to amino acids 228-454 of SEQ ID NO:10; and a second Fc polypeptide comprising an amino acid sequence that is 100% identical to amino acids 228-454 of SEQ ID NO:9. In some embodiments, the Fc dimer comprises: a first Fc polypeptide comprising an amino acid sequence that is 100% identical to amino acids 228-453 of SEQ ID NO:10; and a second Fc polypeptide comprising an amino acid sequence that is 100% identical to amino acids 228-453 of SEQ ID NO:9.

[0172] Any of the described Fc dimers may have an FcRn binding site or one or more mutations that increase or decrease FcRn binding. The term "FcRn" refers to the neonatal Fc receptor. Binding of an Fc peptide to FcRn reduces the clearance of the Fc peptide and increases its serum half-life. Any of the described Fc dimers may have one or more mutations that increase the half-life or serum half-life (e.g., stability) of the Aβ-targeting protein. Such mutations may be any mutations known in the art that increase the half-life or serum half-life of IgG. Known mutations that increase the half-life of IgG include, but are not limited to, mutations at one or more of the following locations: T250, M252, S254, T256, T307, E380, M428, and N434 (according to the EU numbering scheme). In some embodiments, the first Fc polypeptide and / or the second polypeptide in the Fc dimer may comprise: (a) one or more of M252Y, S254T, and T256E substitutions; (b) M428L and / or N434S substitutions; (c) one or more of T307A, E380A, and N434A substitutions; (d) T250Q and / or M428L substitutions; (e) M428L and / or N434S substitutions; and / or (f) N434S and / or N434A substitutions. Mutations regulating FcRn binding may be present in the first PC polypeptide of the Fc dimer, the second Fc polypeptide of the Fc dimer, or both polypeptides of the Fc dimer. Mutations increasing half-life or serum half-life may be present in the first PC polypeptide of the Fc dimer, the second Fc polypeptide of the Fc dimer, or both polypeptides of the Fc dimer.

[0173] In some embodiments, the Fc dimer comprises: (a) a first Fc polypeptide comprising a TfR binding region, amino acid modifications L234A and L235A and optional P329G, and an amino acid modification N434S with or without M428L (according to the EU numbering scheme), and (b) a second Fc polypeptide which does not contain a TfR binding site or any modifications that reduce FcγR binding.

[0174] In some embodiments, the Fc dimer comprises: (a) a first Fc polypeptide comprising a TfR binding region, amino acid modifications L234A and L235A and optional P329G, and an amino acid modification N434S with or without M428L (according to the EU numbering scheme), and (b) a second Fc polypeptide comprising an amino acid modification N434S with or without M428L and without a TfR binding site or any modification that reduces FcγR binding.

[0175] In some embodiments, the Fc dimer or Fc polypeptide as described herein further comprises a partial or complete hinge region. The hinge region may be derived from any immunoglobulin subclass or isotype. An illustrative immunoglobulin hinge is an IgG hinge region, such as the IgG1 hinge region, for example, the human IgG1 hinge amino acid sequence EPKSCDKTHTCPPCP (SEQ ID NO:16). In other embodiments, the Fc polypeptide comprising a hinge or a partial hinge region may be further fused with a polypeptide comprising an Aβ-binding region.

[0176] In some embodiments, an Fc dimer or Fc polypeptide, as described herein, is fused to a polypeptide containing an Aβ-binding region via a linker. The linker can be, but is not limited to, a peptide linker (e.g., a hinge region). The peptide linker can be configured such that it allows the variable region and the Fc polypeptide or Fc dimer to rotate relative to each other; and / or is resistant to digestion by proteases. In some embodiments, the linker can be a flexible linker, for example, containing amino acids such as Gly, Asn, Ser, Thr, Ala, etc. Such linkers are designed using known parameters. For example, the linker can have repeats, such as Gly-Ser or (Gly). m (Ser) n repeat.

[0177] In some embodiments, the Aβ-targeting protein comprises: an Aβ-binding region including a heavy-chain Fab region and a light-chain Fab region, a TfR-binding region including a first Fc polypeptide, and an FcγR-binding region including a second Fc polypeptide, wherein the first Fc polypeptide dimerizes with the second Fc polypeptide. The first or second Fc polypeptide may be linked to the heavy-chain Fab region.

[0178] In some embodiments, the Aβ-targeting protein comprises two Aβ-binding regions (each Aβ-binding region comprising a heavy chain Fab region and a light chain Fab region), a TfR-binding region comprising a first Fc polypeptide, and an FcγR-binding region comprising a second Fc polypeptide, wherein the first Fc polypeptide dimerizes with the second Fc polypeptide, and wherein the first Fc polypeptide is linked to one heavy chain Fab region and the second Fc polypeptide is linked to another heavy chain Fab region. Those skilled in the art will recognize that this conformation is similar to that of an immunoglobulin.

[0179] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0180] (a) A first Fc polypeptide comprising a TfR-binding region that specifically binds to TfR with an affinity of about 900 nM to about 10,000 nM (e.g., about 900 nM to about 2500 nM or about 900 nM to about 1300 nM); and

[0181] (b) The second Fc polypeptide, which contains the FcγR binding region.

[0182] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0183] (a) A first Fc polypeptide comprising a TfR-binding region that specifically binds to TfR with an affinity of about 900 nM to about 10,000 nM (e.g., about 900 nM to about 2500 nM or about 900 nM to about 1300 nM); and

[0184] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region.

[0185] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0186] (a) A first Fc polypeptide comprising a TfR-binding region that specifically binds to TfR with an affinity of about 900 nM to about 10,000 nM (e.g., about 900 nM to about 2500 nM or about 900 nM to about 1300 nM); and

[0187] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region;

[0188] The first Fc polypeptide contains one or more amino acid substitutions that reduce binding to FcγR; and

[0189] The second Fc polypeptide does not contain any modifications that reduce FcγR binding.

[0190] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0191] (a) A first Fc polypeptide comprising a CH3-domain polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity with amino acids 348-454 of any of SEQ ID NO: 8, 10, and 17-31, wherein the polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1; and

[0192] (b) The second Fc polypeptide, which contains the FcγR binding region.

[0193] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0194] (a) A first Fc polypeptide comprising a CH3-domain polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 348-454 of SEQ ID NO: 8 or 10, wherein the first Fc polypeptide has Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme); and

[0195] (b) The second Fc polypeptide, which contains the FcγR binding region.

[0196] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0197] (a) A first Fc polypeptide comprising a CH3-domain polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity with amino acids 348-454 of any of SEQ ID NO: 8, 10, and 17-31, wherein the polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1; and

[0198] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region.

[0199] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0200] (a) A first Fc polypeptide comprising a CH3-domain polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 348-454 of SEQ ID NO: 8 or 10, wherein the first Fc polypeptide has Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme); and

[0201] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region.

[0202] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0203] (a) A first Fc polypeptide comprising a CH3-domain polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% similarity to amino acids 348-454 of any of SEQ ID NO: 8, 10, and 17-31, wherein the polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme), as shown in Table 1; and

[0204] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region and does not contain any modifications that reduce FcγR binding.

[0205] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0206] (a) A first Fc polypeptide comprising a CH3-domain polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 348-454 of SEQ ID NO: 8 or 10, wherein the first Fc polypeptide has Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme); and

[0207] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region and does not contain any modifications that reduce FcγR binding.

[0208] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0209] (a) A first Fc polypeptide comprising a CH3-domain polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity with amino acids 348-454 of any of SEQ ID NO: 8, 10, and 17-31, wherein the polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1 and one or more amino acid substitutions that reduce binding to FcγR; and

[0210] (b) The second Fc polypeptide, which contains the FcγR binding region.

[0211] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0212] (a) A first Fc polypeptide comprising a CH3-domain polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 348-454 of SEQ ID NO: 8 or 10, wherein the first Fc polypeptide has Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme) and one or more amino acid substitutions that reduce binding to FcγR; and

[0213] (b) The second Fc polypeptide, which contains the FcγR binding region.

[0214] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0215] (a) A first Fc polypeptide comprising a CH3-domain polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity with amino acids 348-454 of any of SEQ ID NO: 8, 10, and 17-31, wherein the polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1 and one or more amino acid substitutions that reduce binding to FcγR; and

[0216] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region.

[0217] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0218] (a) A first Fc polypeptide comprising a CH3-domain polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 348-454 of SEQ ID NO: 8 or 10, wherein the first Fc polypeptide has Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme) and one or more amino acid substitutions that reduce binding to FcγR; and

[0219] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region.

[0220] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0221] (a) A first Fc polypeptide comprising a CH3-domain polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity with amino acids 348-454 of any of SEQ ID NO: 8, 10, and 17-31, wherein the polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1 and one or more amino acid substitutions that reduce binding to FcγR; and

[0222] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region and does not contain any modifications that reduce FcγR binding.

[0223] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0224] (a) A first Fc polypeptide comprising a CH3-domain polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 348-454 of SEQ ID NO: 8 or 10, wherein the first Fc polypeptide has Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme) and one or more amino acid substitutions that reduce binding to FcγR; and

[0225] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region and does not contain any modifications that reduce FcγR binding.

[0226] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0227] (a) A first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity with amino acids 348-454 of any of SEQ ID NO: 8, 10, and 17-31, wherein the polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1, and A at position 234 and A at position 235; and

[0228] (b) The second Fc polypeptide, which contains the FcγR binding region.

[0229] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0230] (a) A first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 228-453 or 228-454 of SEQ ID NO: 8 or 10, wherein the first Fc polypeptide has A at position 234, A at position 235, Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme); and

[0231] (b) The second Fc polypeptide, which contains the FcγR binding region.

[0232] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0233] (a) A first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity with amino acids 348-454 of any of SEQ ID NO: 8, 10, and 17-31, wherein the polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1, and amino acids A at position 234, A at position 235, and G at position 329; and

[0234] (b) The second Fc polypeptide, which contains the FcγR binding region.

[0235] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0236] (a) A first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 228-453 or 228-454 of SEQ ID NO: 8 or 10, wherein the first Fc polypeptide has A at position 234, A at position 235, G at position 329, Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme); and

[0237] (b) The second Fc polypeptide, which contains the FcγR binding region.

[0238] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0239] (a) A first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity with amino acids 348-454 of any of SEQ ID NO: 8, 10, and 17-31, wherein the polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1, and A at position 234 and A at position 235; and

[0240] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region.

[0241] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0242] (a) A first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 228-453 or 228-454 of SEQ ID NO: 8 or 10, wherein the first Fc polypeptide has A at position 234, A at position 235, Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme); and

[0243] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region.

[0244] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0245] (a) A first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity with amino acids 348-454 of any of SEQ ID NO: 8, 10, and 17-31, wherein the polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1, and amino acids A at position 234, A at position 235, and G at position 329; and

[0246] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region.

[0247] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0248] (a) A first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 228-453 or 228-454 of SEQ ID NO: 8 or 10, wherein the first Fc polypeptide has A at position 234, A at position 235, G at position 329, Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme); and

[0249] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region.

[0250] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0251] (a) A first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity with amino acids 348-454 of any of SEQ ID NO: 8, 10, and 17-31, wherein the polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1, and A at position 234 and A at position 235; and

[0252] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region and does not contain any modifications that reduce FcγR binding.

[0253] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0254] (a) A first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 228-453 or 228-454 of SEQ ID NO: 8 or 10, wherein the first Fc polypeptide has A at position 234, A at position 235, Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme); and

[0255] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region and does not contain any modifications that reduce FcγR binding.

[0256] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0257] (a) A first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity with amino acids 348-454 of any of SEQ ID NO: 8, 10, and 17-31, wherein the polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1, and amino acids A at position 234, A at position 235, and G at position 329; and

[0258] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region and does not contain any modifications that reduce FcγR binding.

[0259] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0260] (a) A first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 228-453 or 228-454 of SEQ ID NO: 8 or 10, wherein the first Fc polypeptide has A at position 234, A at position 235, G at position 329, Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme); and

[0261] (b) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region and does not contain any modifications that reduce FcγR binding.

[0262] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0263] (a) A first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity with amino acids 348-454 of any of SEQ ID NO: 8, 10, and 17-31, wherein the polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1, and amino acids A at position 234, A at position 235, G optionally at position 329, and W at position 366; and

[0264] (b) A second Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 228-453 or 228-454 of SEQ ID NO:9, wherein the second Fc polypeptide has an S at position 366, an A at position 368, and a V at position 407 (according to the EU numbering scheme), comprises an FcγR binding region, and does not contain a TfR binding region.

[0265] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0266] (a) A first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 228-453 or 228-454 of SEQ ID NO: 8 or 10, wherein the first Fc polypeptide has A at position 234, A at position 235, G optionally at position 329, W at position 366, Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme); and

[0267] (b) A second Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 228-453 or 228-454 of SEQ ID NO:9, wherein the second Fc polypeptide has an S at position 366, an A at position 368, and a V at position 407 (according to the EU numbering scheme), comprises an FcγR binding region, and does not contain a TfR binding region.

[0268] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0269] (a) A first Fc polypeptide comprising the amino acid sequence of amino acids 348-453 or 348-454 of any one of SEQ ID NO: 8, 10, and 17-31; and

[0270] (b) A second Fc polypeptide comprising the amino acid sequence of amino acids 348-453 or 348-454 of SEQ ID NO:9.

[0271] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0272] (a) A first Fc polypeptide comprising the amino acid sequence of amino acids 348-453 or 348-454 of SEQ ID NO:8; and

[0273] (b) A second Fc polypeptide comprising the amino acid sequence of amino acids 348-453 or 348-454 of SEQ ID NO:9.

[0274] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0275] (a) A first Fc polypeptide comprising the amino acid sequence of amino acids 348-453 or 348-454 of SEQ ID NO:10; and

[0276] (b) A second Fc polypeptide comprising the amino acid sequence of amino acids 348-453 or 348-454 of SEQ ID NO:9.

[0277] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0278] (a) A first Fc polypeptide comprising the amino acid sequence 228-453 or 228-454 of any one of SEQ ID NO: 8, 10 and 1-31; and

[0279] (b) A second Fc polypeptide comprising the amino acid sequence of amino acids 228-453 or 228-454 of SEQ ID NO:9.

[0280] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0281] (a) A first Fc polypeptide comprising the amino acid sequence of amino acids 228-453 or 228-454 of SEQ ID NO:8; and

[0282] (b) A second Fc polypeptide comprising the amino acid sequence of amino acids 228-453 or 228-454 of SEQ ID NO:9.

[0283] In some embodiments, the Aβ-targeting protein includes an Aβ-binding region linked to an Fc dimer, wherein the Fc dimer comprises:

[0284] (a) A first Fc polypeptide comprising the amino acid sequence 228-453 or 228-454 of SEQ ID NO:10; and

[0285] (b) A second Fc polypeptide comprising the amino acid sequence of amino acids 228-453 or 228-454 of SEQ ID NO:9.

[0286] In some embodiments, the Aβ-targeting protein comprises a first light chain polypeptide, a second light chain polypeptide, a first heavy chain polypeptide, and a second heavy chain polypeptide, wherein:

[0287] (a) The first and second light chain polypeptides each contain a VL, which contains a VLCDR1 having the amino acid sequence of SEQ ID NO:4, a VLCDR2 having the amino acid sequence of SEQ ID NO:5, and a VLCDR3 having the amino acid sequence of SEQ ID NO:6.

[0288] (b) The first heavy chain polypeptide contains

[0289] (i) VH, comprising VHCDR1 having the amino acid sequence of SEQ ID NO:1, VHCDR2 having the amino acid sequence of SEQ ID NO:2, and VHCDR3 having the amino acid sequence of SEQ ID NO:3, and

[0290] (ii) a first Fc polypeptide comprising a TfR-binding region that specifically binds to TfR with an affinity of about 900 nM to about 10,000 nM (e.g., about 900 nM to about 2500 nM or about 900 nM to about 1300 nM); and

[0291] (c) The second heavy chain polypeptide contains

[0292] (i) VH, comprising VHCDR1 having the amino acid sequence of SEQ ID NO:1, VHCDR2 having the amino acid sequence of SEQ ID NO:2, and VHCDR3 having the amino acid sequence of SEQ ID NO:3, and

[0293] (ii) A second Fc polypeptide containing an FcγR binding region.

[0294] The first light chain polypeptide forms a dimer with the first heavy chain to form an Aβ binding domain, the second light chain polypeptide forms a dimer with the second heavy chain to form an Aβ binding domain, and the first Fc polypeptide forms an Fc dimer with the second Fc polypeptide.

[0295] In some embodiments, the Aβ-targeting protein comprises a first light chain polypeptide, a second light chain polypeptide, a first heavy chain polypeptide, and a second heavy chain polypeptide, wherein:

[0296] (a) The first and second light chain polypeptides each comprise a VL, which comprises an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to amino acids 1-109 of SEQ ID NO:7, a VLCDR1 having an amino acid sequence of SEQ ID NO:4, a VLCDR2 having an amino acid sequence of SEQ ID NO:5, and a VLCDR3 having an amino acid sequence of SEQ ID NO:6;

[0297] (b) The first heavy chain polypeptide contains

[0298] (i) VH, comprising an amino acid sequence having at least 85%, at least 90%, at least 95%, or 100% identity with amino acids 1-120 of any of SEQ ID NO: 8, 10, and 17-31; VHCDR1 having the amino acid sequence of SEQ ID NO: 1; VHCDR2 having the amino acid sequence of SEQ ID NO: 2; and VHCDR3 having the amino acid sequence of SEQ ID NO: 3; and

[0299] (ii) A first Fc polypeptide comprising a CH3 domain polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% similarity to amino acids 348-454 of any of SEQ ID NO: 8, 10, and 17-31, wherein the polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1;

[0300] (iii) Optionally, the CH3 domain polypeptide includes one or more of the following: A at position 234, A at position 235, G at position 329, and W at position 366.

[0301] (c) The second heavy chain polypeptide contains

[0302] (i) VH, comprising an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to amino acids 1-120 of SEQ ID NO: 8 or 10, VHCDR1 having the amino acid sequence of SEQ ID NO: 1, VHCDR2 having the amino acid sequence of SEQ ID NO: 2, and VHCDR3 having the amino acid sequence of SEQ ID NO: 3; and

[0303] (ii) A second Fc polypeptide comprising an FcγR binding region, optionally wherein the second Fc polypeptide does not contain a TfR binding region, optionally wherein the second Fc polypeptide comprises an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 228-453 or 228-454 of SEQ ID NO:9, optionally wherein the second Fc polypeptide has an S at position 366, an A at position 368, and a V at position 407 (according to the EU numbering scheme);

[0304] The first light chain polypeptide forms a dimer with the first heavy chain to form an Aβ binding domain, the second light chain polypeptide forms a dimer with the second heavy chain to form an Aβ binding domain, and the first Fc polypeptide forms an Fc dimer with the second Fc polypeptide.

[0305] In some embodiments, the Aβ-targeting protein comprises a first light chain polypeptide, a second light chain polypeptide, a first heavy chain polypeptide, and a second heavy chain polypeptide, wherein:

[0306] (a) The first and second light chain polypeptides each comprise a VL, which comprises an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to amino acids 1-109 of SEQ ID NO:7, a VLCDR1 having an amino acid sequence of SEQ ID NO:4, a VLCDR2 having an amino acid sequence of SEQ ID NO:5, and a VLCDR3 having an amino acid sequence of SEQ ID NO:6;

[0307] (b) The first heavy chain polypeptide contains

[0308] (i) VH, comprising an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to amino acids 1-120 of SEQ ID NO: 8 or 10, VHCDR1 having the amino acid sequence of SEQ ID NO: 1, VHCDR2 having the amino acid sequence of SEQ ID NO: 2, and VHCDR3 having the amino acid sequence of SEQ ID NO: 3; and

[0309] (ii) A first Fc polypeptide comprising a CH3-domain polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 348-454 of SEQ ID NO: 8 or 10, wherein the first Fc polypeptide has Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme); and

[0310] (c) The second heavy chain polypeptide contains

[0311] (i) VH, comprising an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to amino acids 1-120 of SEQ ID NO: 8 or 10, VHCDR1 having the amino acid sequence of SEQ ID NO: 1, VHCDR2 having the amino acid sequence of SEQ ID NO: 2, and VHCDR3 having the amino acid sequence of SEQ ID NO: 3; and

[0312] (ii) A second Fc polypeptide containing an FcγR binding region.

[0313] The first light chain polypeptide forms a dimer with the first heavy chain to form an Aβ binding domain, the second light chain polypeptide forms a dimer with the second heavy chain to form an Aβ binding domain, and the first Fc polypeptide forms an Fc dimer with the second Fc polypeptide.

[0314] In some embodiments, the Aβ-targeting protein comprises a first light chain polypeptide, a second light chain polypeptide, a first heavy chain polypeptide, and a second heavy chain polypeptide, wherein:

[0315] (a) The first and second light chain polypeptides each comprise a VL, which comprises an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to amino acids 1-109 of SEQ ID NO:7, a VLCDR1 having an amino acid sequence of SEQ ID NO:4, a VLCDR2 having an amino acid sequence of SEQ ID NO:5, and a VLCDR3 having an amino acid sequence of SEQ ID NO:6;

[0316] (b) The first heavy chain polypeptide contains

[0317] (i) VH, comprising an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to amino acids 1-120 of SEQ ID NO: 8 or 10, VHCDR1 having the amino acid sequence of SEQ ID NO: 1, VHCDR2 having the amino acid sequence of SEQ ID NO: 2, and VHCDR3 having the amino acid sequence of SEQ ID NO: 3; and

[0318] (ii) A first Fc polypeptide comprising a CH3-domain polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 348-454 of SEQ ID NO: 8 or 10, wherein the first Fc polypeptide has Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme) and one or more amino acid substitutions that reduce binding to FcγR; and

[0319] (c) The second heavy chain polypeptide contains

[0320] (i) VH, comprising an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to amino acids 1-120 of SEQ ID NO: 8 or 10, VHCDR1 having the amino acid sequence of SEQ ID NO: 1, VHCDR2 having the amino acid sequence of SEQ ID NO: 2, and VHCDR3 having the amino acid sequence of SEQ ID NO: 3; and

[0321] (ii) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region.

[0322] The first light chain polypeptide forms a dimer with the first heavy chain to form an Aβ binding domain, the second light chain polypeptide forms a dimer with the second heavy chain to form an Aβ binding domain, and the first Fc polypeptide forms an Fc dimer with the second Fc polypeptide.

[0323] In some embodiments, the Aβ-targeting protein comprises a first light chain polypeptide, a second light chain polypeptide, a first heavy chain polypeptide, and a second heavy chain polypeptide, wherein:

[0324] (a) The first and second light chain polypeptides each comprise a VL, which comprises an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to amino acids 1-109 of SEQ ID NO:7, a VLCDR1 having an amino acid sequence of SEQ ID NO:4, a VLCDR2 having an amino acid sequence of SEQ ID NO:5, and a VLCDR3 having an amino acid sequence of SEQ ID NO:6;

[0325] (b) The first heavy chain polypeptide contains

[0326] (i) VH, comprising an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to amino acids 1-120 of SEQ ID NO: 8 or 10, VHCDR1 having the amino acid sequence of SEQ ID NO: 1, VHCDR2 having the amino acid sequence of SEQ ID NO: 2, and VHCDR3 having the amino acid sequence of SEQ ID NO: 3; and

[0327] (ii) A first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 228-453 or 228-454 of SEQ ID NO: 8 or 10, wherein the first Fc polypeptide has A at position 234, A at position 235, G optionally at position 329, Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme); and

[0328] (c) The second heavy chain polypeptide contains

[0329] (i) VH, comprising an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to amino acids 1-120 of SEQ ID NO: 8 or 10, VHCDR1 having the amino acid sequence of SEQ ID NO: 1, VHCDR2 having the amino acid sequence of SEQ ID NO: 2, and VHCDR3 having the amino acid sequence of SEQ ID NO: 3; and

[0330] (ii) A second Fc polypeptide containing an FcγR binding region, wherein the second Fc polypeptide does not contain a TfR binding region.

[0331] The first light chain polypeptide forms a dimer with the first heavy chain to form an Aβ binding domain, the second light chain polypeptide forms a dimer with the second heavy chain to form an Aβ binding domain, and the first Fc polypeptide forms an Fc dimer with the second Fc polypeptide.

[0332] In some embodiments, the Aβ-targeting protein comprises a first light chain polypeptide, a second light chain polypeptide, a first heavy chain polypeptide, and a second heavy chain polypeptide, wherein:

[0333] (a) The first and second light chain polypeptides each comprise a VL, which comprises an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to amino acids 1-109 of SEQ ID NO:7, a VLCDR1 having an amino acid sequence of SEQ ID NO:4, a VLCDR2 having an amino acid sequence of SEQ ID NO:5, and a VLCDR3 having an amino acid sequence of SEQ ID NO:6;

[0334] (b) The first heavy chain polypeptide contains

[0335] (i) VH, comprising an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to amino acids 1-120 of SEQ ID NO: 8 or 10, VHCDR1 having the amino acid sequence of SEQ ID NO: 1, VHCDR2 having the amino acid sequence of SEQ ID NO: 2, and VHCDR3 having the amino acid sequence of SEQ ID NO: 3; and

[0336] (ii) A first Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similarity to amino acids 228-453 or 228-454 of SEQ ID NO: 8 or 10, wherein the first Fc polypeptide has A at position 234, A at position 235, G optionally at position 329, W at position 366, Y at position 384, T at position 386, E at position 387, W at position 388, V at position 389, T at position 413, E at position 415, E at position 416, and F at position 421 (according to the EU numbering scheme); and

[0337] (c) The second heavy chain polypeptide contains

[0338] (i) VH, comprising an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to amino acids 1-120 of SEQ ID NO: 8 or 10, VHCDR1 having the amino acid sequence of SEQ ID NO: 1, VHCDR2 having the amino acid sequence of SEQ ID NO: 2, and VHCDR3 having the amino acid sequence of SEQ ID NO: 3; and

[0339] (ii) A second Fc polypeptide comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity with amino acids 228-453 or 228-454 of SEQ ID NO:9, wherein the second Fc polypeptide has an S at position 366, an A at position 368, and a V at position 407 (according to the EU numbering scheme), contains an FcγR binding region, and does not contain a TfR binding region.

[0340] The first light chain polypeptide forms a dimer with the first heavy chain to form an Aβ binding domain, the second light chain polypeptide forms a dimer with the second heavy chain to form an Aβ binding domain, and the first Fc polypeptide forms an Fc dimer with the second Fc polypeptide.

[0341] In some embodiments, the Aβ-targeting protein comprises a first light chain polypeptide, a second light chain polypeptide, a first heavy chain polypeptide, and a second heavy chain polypeptide, wherein:

[0342] (a) The first and second light chain polypeptides each contain the amino acid sequence of SEQ ID NO:7;

[0343] (b) The first heavy chain polypeptide comprises the amino acid sequence 1-453 or 1-454 of any of SEQ ID NO: 8, 10 and 17-31; and

[0344] (c) The second heavy chain polypeptide contains the amino acid sequence of amino acids 1-453 or 1-454 of SEQ ID NO:9.

[0345] The first light chain polypeptide forms a dimer with the first heavy chain to form an Aβ binding domain, the second light chain polypeptide forms a dimer with the second heavy chain to form an Aβ binding domain, and the first Fc polypeptide forms an Fc dimer with the second Fc polypeptide.

[0346] In some embodiments, the Aβ-targeting protein comprises a first light chain polypeptide, a second light chain polypeptide, a first heavy chain polypeptide, and a second heavy chain polypeptide, wherein:

[0347] (a) The first and second light chain polypeptides each contain the amino acid sequence of SEQ ID NO:7;

[0348] (b) The first heavy chain polypeptide comprises the amino acid sequence of amino acids 1-453 or 1-454 of SEQ ID NO:8; and

[0349] (c) The second heavy chain polypeptide contains the amino acid sequence of amino acids 1-453 or 1-454 of SEQ ID NO:9.

[0350] The first light chain polypeptide forms a dimer with the first heavy chain to form an Aβ binding domain, the second light chain polypeptide forms a dimer with the second heavy chain to form an Aβ binding domain, and the first Fc polypeptide forms an Fc dimer with the second Fc polypeptide.

[0351] In some embodiments, the Aβ-targeting protein comprises a first light chain polypeptide, a second light chain polypeptide, a first heavy chain polypeptide, and a second heavy chain polypeptide, wherein:

[0352] (a) The first and second light chain polypeptides each contain the amino acid sequence of SEQ ID NO:7;

[0353] (b) The first heavy chain polypeptide comprises the amino acid sequence 1-453 or 1-454 of SEQ ID NO:10; and

[0354] (c) The second heavy chain polypeptide contains the amino acid sequence of amino acids 1-453 or 1-454 of SEQ ID NO:9.

[0355] The first light chain polypeptide forms a dimer with the first heavy chain to form an Aβ binding domain, the second light chain polypeptide forms a dimer with the second heavy chain to form an Aβ binding domain, and the first Fc polypeptide forms an Fc dimer with the second Fc polypeptide.

[0356] In some embodiments, the Aβ-targeting protein comprises a first light chain polypeptide, a second light chain polypeptide, a first heavy chain polypeptide, and a second heavy chain polypeptide, wherein:

[0357] (a) The first and second light chain polypeptides each consist of the amino acid sequence of SEQ ID NO:7;

[0358] (b) The first heavy chain polypeptide consists of the amino acid sequence 1-453 or 1-454 of any of SEQ ID NO: 8, 10 and 17-31; and

[0359] (c) The second heavy chain polypeptide consists of the amino acid sequence of amino acids 1-453 or 1-454 of SEQ ID NO:9.

[0360] The first light chain polypeptide forms a dimer with the first heavy chain to form an Aβ binding domain, the second light chain polypeptide forms a dimer with the second heavy chain to form an Aβ binding domain, and the first Fc polypeptide forms an Fc dimer with the second Fc polypeptide.

[0361] In some embodiments, the Aβ-targeting protein comprises a first light chain polypeptide, a second light chain polypeptide, a first heavy chain polypeptide, and a second heavy chain polypeptide, wherein:

[0362] (a) The first and second light chain polypeptides each consist of the amino acid sequence of SEQ ID NO:7;

[0363] (b) The first heavy chain polypeptide consists of the amino acid sequence of amino acids 1-453 or 1-454 of SEQ ID NO:8; and

[0364] (c) The second heavy chain polypeptide consists of the amino acid sequence of amino acids 1-453 or 1-454 of SEQ ID NO:9.

[0365] The first light chain polypeptide forms a dimer with the first heavy chain to form an Aβ binding domain, the second light chain polypeptide forms a dimer with the second heavy chain to form an Aβ binding domain, and the first Fc polypeptide forms an Fc dimer with the second Fc polypeptide.

[0366] In some embodiments, the Aβ-targeting protein comprises a first light chain polypeptide, a second light chain polypeptide, a first heavy chain polypeptide, and a second heavy chain polypeptide, wherein:

[0367] (a) The first and second light chain polypeptides each consist of the amino acid sequence of SEQ ID NO:7;

[0368] (b) The first heavy chain polypeptide consists of the amino acid sequence of amino acids 1-453 or 1-454 of SEQ ID NO:10; and

[0369] (c) The second heavy chain polypeptide consists of the amino acid sequence of amino acids 1-453 or 1-454 of SEQ ID NO:9.

[0370] The first light chain polypeptide forms a dimer with the first heavy chain to form an Aβ binding domain, the second light chain polypeptide forms a dimer with the second heavy chain to form an Aβ binding domain, and the first Fc polypeptide forms an Fc dimer with the second Fc polypeptide.

[0371] In other embodiments, the Aβ-targeting protein may be fused to a peptide or protein that can be used for protein purification. Such peptides include, but are not limited to, polyhistidine, epitope tags (e.g., FLAG, c-Myc, and hemagglutinin tags), glutathione S-transferase (GST), thioredoxin, protein A, protein G, and maltose-binding protein (MBP). In some cases, the fused peptide or protein may contain a protease cleavage site, such as the cleavage site of factor Xa or thrombin. In some embodiments, the ligation may be cleaved by enzymes present in the central nervous system.

[0372] III. Nucleic Acids, Vectors, and Host Cells

[0373] The Aβ-targeting proteins described herein can be prepared using recombinant methods. Therefore, isolated nucleic acids containing sequences encoding any of the Aβ-targeting proteins or portions thereof described herein can be readily generated using methods available in the art. Nucleic acids introduced and usable for replicating polypeptides and / or host cells expressing polypeptides are also available in the art. Host cells can be, but are not limited to, prokaryotic or eukaryotic cells. Eukaryotic cells can be, but are not limited to, yeast cells, insect cells, or mammalian cells (e.g., human cells).

[0374] The nucleic acid encoding the Aβ target protein or a portion thereof can be DNA, RNA, cDNA, mRNA, single-stranded, double-stranded, linear, or circular.

[0375] In some embodiments, the nucleic acid encoding the Aβ target protein comprises a nucleic acid sequence encoding a polypeptide having at least 85%, at least 90%, or at least 95% identity with any of SEQ ID NO: 8, 10, and 17-31, wherein the encoded polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 (according to the EU numbering scheme) as shown in Table 1. In some embodiments, the encoded polypeptide further comprises: (a) alanine at position 234, alanine at position 235, (b) alanine at position 234, alanine at position 235, and glycine at position 329, or (c) alanine at position 234, alanine at position 235, glycine at position 329, and tryptophan at position 366.

[0376] In some embodiments, the nucleic acid encoding the Aβ target protein comprises a nucleic acid sequence encoding a polypeptide having at least 85%, at least 90%, or at least 95% identity with SEQ ID NO: 8 or 10, wherein the encoded polypeptide contains: (a) alanine at position 234, alanine at position 235, glycine at position 329, tryptophan at position 366, tyrosine at position 384, threonine at position 386, glutamic acid at position 387, tryptophan at position 388, valine at position 389, threonine at position 413, and valine at position 415. Glutamic acid, glutamic acid at position 416 and phenylalanine at position 421; or (b) alanine at position 234, alanine at position 235, tryptophan at position 366, tyrosine at position 384, threonine at position 386, glutamic acid at position 387, tryptophan at position 388, valine at position 389, threonine at position 413, glutamate at position 415, glutamic acid at position 416 and phenylalanine at position 421 (according to the EU numbering scheme).

[0377] Aβ-targeting proteins may comprise two or more (e.g., three) polypeptides, each encoded by a separate nucleic acid sequence. These separate nucleic acid sequences may be present on the same plasmid or vector, or on different plasmids or vectors. If present on the same plasmid or vector, the separate nucleic acid sequences may be expressed from a single promoter or from different promoters. Methods for expressing nucleic acids encoding separate polypeptides from a single promoter are known in the art and include, but are not limited to, the use of 2A elements and internal ribosome entry sites.

[0378] Nucleic acid encoding the Aβ target protein or a portion thereof can be provided in plasmids or vectors. Plasmids or vectors can be used to replicate nucleic acids or promote nucleic acid expression. Plasmids or vectors can be, but are not limited to, viral vectors, phage particles, yeast chromosome vectors, or non-attachment mammalian vectors.

[0379] In some implementations, a nucleic acid encoding an Aβ-targeting protein or a portion thereof is operatively linked to one or more regulatory sequences in the expression construct. The expression construct may be adapted to express the peptide in a system that generates the Aβ-targeting protein. Such systems may be, but are not limited to, mammalian cell expression systems, insect cell expression systems, yeast cell expression systems, or bacterial cell expression systems.

[0380] Expression media used to generate recombinant peptides include plasmids and other vectors. Suitable vectors, for example, include plasmids of the following types: pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids, and pETC-derived plasmids for expression in prokaryotic cells such as *E. coli*. pcDNAI / amp, pcDNAEneo, pRc / CMV, pSV2gpt, pSV2neo, pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo, and pHyg-derived vectors are examples of mammalian expression vectors suitable for transfecting eukaryotic cells. Alternatively, viral derivatives, such as bovine papillomavirus (BPV-1) or Epstein-Barr virus (pHEBo, pREP-derived, and p205), can be used for transient expression of peptides in eukaryotic cells. In some embodiments, it may be necessary to express recombinant peptides using a baculovirus expression system. Examples of such baculovirus expression systems include pVL-derived vectors (such as pVLl392, pVLl393, and pVL94l), pAcUW-derived vectors (such as pAcUWl), and pBlueBac-derived vectors. Other expression systems include adenovirus, adeno-associated virus, and other viral expression systems.

[0381] Expression vectors containing nucleic acids, specifically plasmids or vectors for expressing Aβ-targeting proteins or a portion thereof, can be transformed, transfected, or transduced into host cells. Host cells can be, but are not limited to, mammalian cells, yeast cells, insect cells, prokaryotic cells, Chinese hamster ovary (CHO) cells, young hamster kidney (BHK) cells, NSO cells, YO cells, HEK293 cells, COS cells, Vero cells, or HeLa cells. Host cells containing the expression vector can be cultured under appropriate conditions to allow expression of the Aβ-targeting protein or a portion thereof.

[0382] The Aβ-targeting protein can be manufactured by culturing a host cell containing one or more nucleic acids encoding an Aβ-targeting protein, expressing the Aβ-targeting protein, and isolating the expressed Aβ-targeting protein from the culture. In some embodiments, the host cell comprises: (a) a first nucleic acid encoding a polypeptide having at least 85%, at least 90%, at least 95%, or 100% similarity to any one of SEQ ID NO:8, 10, or 17-31; (b) a second nucleic acid encoding a polypeptide having at least 85%, at least 90%, at least 95%, or 100% similarity to SEQ ID NO:9; and (c) a third nucleic acid encoding a polypeptide having at least 85%, at least 90%, at least 95%, or 100% similarity to SEQ ID NO:7.

[0383] IV. Preparations

[0384] Any of the described Aβ-targeting proteins can be prepared, provided, or formulated as a salt, mixed salt, or free acid. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium, potassium, calcium, and magnesium salts.

[0385] Any of the described Aβ-targeting proteins may be provided or formulated in a pharmaceutical composition. A pharmaceutical composition or agent comprises a pharmaceutically effective amount of at least one described Aβ-targeting protein and optionally one or more pharmaceutically acceptable excipients. A pharmaceutically acceptable excipient is a substance intentionally included in a pharmaceutical composition other than the active pharmaceutical ingredient (API, therapeutic product (e.g., Aβ-targeting protein)). The excipient does not exert or is not intended to exert a therapeutic effect at the intended dose. The excipient may be used to (a) assist in the processing of the API during manufacturing, (b) protect, support, or enhance the stability, bioavailability, or patient acceptability of the API, (c) assist in product identification, and / or (d) enhance any other properties of the API's overall safety, efficacy, or delivery during storage or use. Pharmaceutically acceptable excipients may or may not be inert substances.

[0386] Excipients include, but are not limited to: absorption enhancers, anti-adhesion agents, defoamers, antioxidants, adhesives, buffers, carriers, coating agents, colorants, delivery enhancers, delivery polymers, dextran, dextran, diluents, disintegrants, emulsifiers, extenders, fillers, fragrances, flow aids, humectants, lubricants, oils, polymers, preservatives, brine, salt, solvents, sugars, suspending agents, sustained-release matrices, sweeteners, thickeners, tensioning agents, mediators, waterproofing agents, and wetting agents.

[0387] The carrier can be, but is not limited to, a solvent or dispersion medium containing, for example, water, brine, phosphate-buffered saline, Ringer's solution, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. The carrier may also contain adjuvants or additives, such as preservatives, wetting agents, emulsifiers, and dispersants. The carrier may also contain isotonic agents, such as sugars, polyols, sodium chloride, etc.

[0388] Pharmaceutical compositions may contain other additional components commonly found in pharmaceutical compositions. Such additional components may include, but are not limited to, antipruritic agents, astringents, local anesthetics, or anti-inflammatory agents (e.g., antihistamines, diphenhydramine, etc.).

[0389] Pharmacologically acceptable refers to those properties and / or substances that are acceptable to a subject from a pharmacological / toxicological perspective. The phrase "pharmacologically acceptable" means that the molecular entity, composition, and properties are physiologically tolerable and generally do not produce allergic or other adverse or toxic reactions when administered to a subject. In some implementations, pharmaceutically acceptable compounds are approved by federal or state regulatory agencies or listed in the United States Pharmacopeia or other recognized pharmacopoeias for use in animals, and more particularly in humans.

[0390] In some embodiments, the pharmaceutical composition further comprises one or more additional active ingredients. These additional active pharmaceutical ingredients may be, but are not limited to, small molecule drugs.

[0391] Aβ-targeting proteins or pharmaceutical compositions containing Aβ-targeting proteins can be formulated as liquid or solid dosage forms (including powders or lyophilized formulations; for example, lyophilized cakes or powders).

[0392] In some embodiments, the pharmaceutical compositions described herein may be formulated for administration to a subject.

[0393] As disclosed above, Aβ-targeting proteins or pharmaceutical compositions containing Aβ-targeting proteins can be formulated for parenteral administration by injection, such as by bolus or continuous infusion. For injection, the Aβ-targeting protein can be formulated by dissolving, suspending, or emulsifying it in an aqueous or non-aqueous solvent (such as vegetable oils or other similar oils, synthetic aliphatic acid glycerides, higher aliphatic acids, or esters of propylene glycol); and, if desired, with conventional additives (such as solubilizers, isotonic agents, suspending agents, emulsifiers, stabilizers, and preservatives). In some embodiments, the peptide can be formulated in an aqueous solution, preferably in a physiologically compatible buffer such as Hanks' solution, Ringer's solution, or physiological saline buffer. Injectable formulations can be presented in a single dosage form, such as in ampoules or in multi-dose containers, with added preservatives. The composition can be in the form of a suspension, solution, or emulsion, such as in an oily or aqueous medium, and can contain formulations such as suspending agents, stabilizers, and / or dispersants.

[0394] Typically, pharmaceutical compositions intended for internal administration are sterile. Sterilization can be performed using methods known in the art, such as heat sterilization, steam sterilization, sterile filtration, or radiation.

[0395] The dosage and desired drug concentration of the pharmaceutical composition of the present invention may vary depending on the specific intended use. The determination of the appropriate dosage or route of administration is within the skill of a person skilled in the art.

[0396] A. Reagent kit

[0397] In some embodiments, a kit is provided that contains an Aβ-targeting protein as described herein. In some embodiments, the kit is used for the prevention or treatment of Aβ-related neurological disorders.

[0398] The described Aβ-targeting proteins and pharmaceutical compositions containing the Aβ-targeting proteins disclosed herein may be packaged or included in kits, containers, packages, or dispensers. Aβ-targeting proteins and pharmaceutical compositions containing Aβ-targeting proteins may be packaged in pre-filled syringes or vials. Any of the Aβ-targeting proteins described herein or pharmaceutical compositions containing Aβ-targeting proteins may be formulated or packaged in single-dose or multi-dose formulations. Any of the Aβ-targeting proteins identified herein or pharmaceutical compositions containing the described Aβ-targeting proteins may be formulated for repeated administration.

[0399] In some embodiments, the kit further comprises one or more additional therapeutic agents. For example, in some embodiments, the kit comprises a transferrin receptor-binding peptide as described herein and further comprises one or more additional therapeutic agents for treating neurological disorders.

[0400] The kit or packaging may further include instructions for use. Instructions for use include documentation describing the relevant materials or methods in relation to the kit. Instructions for use may include one or more of the following: background information, a list of components and their availability information (purchase information, etc.), a brief or detailed protocol for using the kit, troubleshooting guidelines, references, technical support, indications, usage, dosage, administration, contraindications and / or warnings regarding drug use, and any other relevant documentation. Instructions for use may be provided with the kit or as a separate component, in print or electronic form. Instructions for use may include a notification as prescribed by the government agency regulating the manufacture, use, or sale of the drug or biological product, reflecting the approval for human use by the manufacturing, using, or selling organization.

[0401] V. Treatment Methods

[0402] The described Aβ-targeting protein can be used to deliver compounds with Aβ binding and effector functions into the brain of a subject, i.e., across the blood-brain barrier.

[0403] The described Aβ-targeting proteins can be administered to subjects to treat diseases or disorders mediated at least in part by β-amyloid or β-amyloid plaques. Upon administration to subjects, the described Aβ-targeting proteins translocate across the BBB to the brain, where they bind to amyloid plaques, cerebrovascular Aβ, or diffuse Aβ deposits. The binding of Aβ-initiating proteins to amyloid plaques, cerebrovascular Aβ, or diffuse Aβ can promote immune responses against amyloid plaques, cerebrovascular Aβ, or diffuse Aβ, such as ADCP.

[0404] A method for treating a subject suffering from a disease or disorder mediated at least partially by β-amyloid or β-amyloid plaques is described, comprising administering to the subject an Aβ-targeting protein or a composition containing an Aβ-targeting protein. In some embodiments, the disease or disorder mediated at least partially by β-amyloid or β-amyloid plaques includes neurodegenerative diseases or disorders. Neurodegenerative diseases may be, but are not limited to, Alzheimer's disease.

[0405] A method for reducing amyloid plaques in the brain of a subject is described, comprising administering an Aβ-targeting protein or a composition containing an Aβ-targeting protein to the subject. Reduction of amyloid plaques may include enhancing Aβ phagocytosis and / or increasing microglia recruitment to Aβ-positive plaques in the subject. In some embodiments, the subject has or is diagnosed with a neurodegenerative disease, or is at increased risk of developing a neurodegenerative disease. In some embodiments, the neurodegenerative disease is Alzheimer's disease.

[0406] A method for reducing amyloid plaques in the brain of a subject is described, comprising administering an Aβ-targeting protein or a composition containing an Aβ-targeting protein to the subject. In some embodiments, the subject has or is diagnosed with a neurodegenerative disease, or has an increased risk of developing a neurodegenerative disease. In some embodiments, the neurodegenerative disease is Alzheimer's disease.

[0407] Methods for treating cognitive impairment, memory loss, and / or dementia in subjects, comprising administering an Aβ-targeting protein or a composition containing an Aβ-targeting protein to the subject. In some embodiments, the subject has or is diagnosed with a neurodegenerative disease, or has an increased risk of developing a neurodegenerative disease. In some embodiments, the neurodegenerative disease is Alzheimer's disease.

[0408] A method for treating loss of neuronal connectivity in the brain of a subject is described, comprising administering an Aβ-targeting protein or a composition containing an Aβ-targeting protein to the subject. In some embodiments, the subject has or is diagnosed with a neurodegenerative disease, or has an increased risk of developing a neurodegenerative disease. In some embodiments, the neurodegenerative disease is Alzheimer's disease.

[0409] A method for delaying or preventing one or more symptoms or pathological conditions at least partially associated with the accumulation of amyloid plaques in the brain of a subject, comprising administering an Aβ-targeting protein or a composition containing an Aβ-targeting protein to the subject. In some embodiments, the subject has or is diagnosed with a neurodegenerative disease, or has an increased risk of developing a neurodegenerative disease. In some embodiments, the neurodegenerative disease is Alzheimer's disease.

[0410] A method for reducing amyloid-associated imaging abnormalities (ARIA) in subjects is described, comprising administering an Aβ-targeting protein or a composition containing an Aβ-targeting protein to the subject. In some embodiments, the subject has or has been diagnosed with a neurodegenerative disease, or has an increased risk of developing a neurodegenerative disease. In some embodiments, the neurodegenerative disease is Alzheimer's disease. In some embodiments, the subject is receiving or plans to receive treatment for a neurodegenerative disease such as Alzheimer's disease. In some embodiments, ARIA is associated with treatment for a neurodegenerative disease such as Alzheimer's disease. In some embodiments, the treatment for a neurodegenerative disease such as Alzheimer's disease is a therapeutic antibody.

[0411] In some implementations, ARIA includes two types of MRI signal abnormalities: ARIA-E (edema / effusion) and ARIA-H (hemoglobinosis / microbleeds). ARIA-E refers to the extravasation of protein fluids, resulting in interstitial vascular edema or sulcal effusion in the pia mater / subpia mater. These manifest as high-signal solid or sulcal abnormalities on T2-weighted and fluid attenuation inversion recovery (FLAIR) sequences. ARIA-H refers to microhemorrhages (mH) or large hemorrhages observed as low-intensity hemosiderin deposition. These reflect iron accumulation following hemoglobin breakdown on gradient recall echo (GRE) / T2* images or under enhanced visualization via susceptibility-weighted imaging (SWI) sequences. In some implementations, the method can reduce ARIA-E events. Incidence. In some implementations, the method can reduce the incidence of ARIA-H events. Incidence rate. In other implementations, the method can reduce the incidence of both ARIA-E and ARIA-H events. Incidence rate.

[0412] Aβ-targeting protein can be administered parenterally, intravenously, or intrathecally, via epidural or intraventricular administration. Administration can be by bolus, infusion, or a combination thereof. Infusion can be administered over a period of approximately 10 to approximately 30 minutes, or over a period of at least 1 hour to approximately 4 hours or longer.

[0413] Aβ-targeting proteins can be administered in combination with one or more additional therapies. These additional therapies may include, but are not limited to, agents that can be used to treat Alzheimer's disease.

[0414] A. Alzheimer's disease

[0415] Alzheimer's disease (AD) is a type of dementia primarily identified through clinical diagnosis and confirmed by disease markers. AD is a continuum with certain operationally defined stages of disease progression. AD pathology begins before the onset of clinical symptoms. Amyloid plaques (a marker of AD pathology) can form 10–20 years before the onset of AD-related dementia. Currently recognized AD stages include preclinical, prodromal, mild, moderate, and severe, but these stages are neither discrete nor distinct. However, AD stages and progression can be monitored by measuring or assessing β-amyloid accumulation (CSF / PET), synaptic dysfunction (FDG-PET / fMRI), tau-mediated neuronal damage (CSF), brain structure (volume MRI), cognition, and clinical function. Systems used for the diagnosis and monitoring of AD include, but are not limited to: the International Working Group (IWG) new AD diagnostic research criteria (Dubois B et al., Lancet Neurol 2007; 6(8):734-736), the IWG research criteria (Dubois et al., Lancet Neurol 2010; 9(11):1118-27), the NIA / AA criteria (Jack CR et al., Alzheimer's Dement 2011; 7(3):257-62) and the DSM-5 criteria (American Psychiatric Association, DSM-5, 2013).

[0416] The described Aβ-targeting protein can be administered to a subject to treat a disease or disorder associated with β-amyloid, or to reduce β-amyloid plaques in the subject's brain. In some embodiments, treating a disease or disorder associated with β-amyloid comprises: (a) alleviating or improving a β-amyloid-related disease; (b) alleviating or improving one or more symptoms or pathological conditions associated with a β-amyloid-related disease; or (c) reducing β-amyloid plaques in the subject's brain; or (d) preventing or delaying at least one symptom or pathological condition in a subject who has a β-amyloid-related disease or is at risk of developing the disease; or (e) prolonging the survival of a subject diagnosed with a β-amyloid-related disease. In some embodiments, treating a disease or disorder associated with β-amyloid comprises reducing amyloid-associated imaging abnormalities (AIRA) in the subject. In some embodiments, the disease or disorder associated with β-amyloid (β-amyloid-related disease) is a neurodegenerative disease. In some embodiments, the neurodegenerative disease is AD. Pathological conditions associated with β-amyloid-related diseases include, but are not limited to: cognitive impairment, memory loss, dementia, or loss of neuronal connections in the brain.

[0417] A method for treating a subject (e.g., a human subject) who has a pathological condition or is at risk of developing a pathological condition at least partially mediated by β-amyloid protein is described, the method comprising administering to the subject an effective amount (e.g., a therapeutically effective amount or a preventatively effective amount) of an Aβ-targeting protein or a composition containing an Aβ-targeting protein. Administering the Aβ-targeting protein or a composition containing an Aβ-targeting protein to the subject may optionally be combined with one or more steps of administering one or more additional (i.e., second, third, etc.) therapeutic agents or treatments.

[0418] In some embodiments, the method further comprises administering one or more additional therapeutic agents to the subject. For example, in some embodiments for treating brain or central nervous system disorders, the method may comprise administering a neuroprotective agent to the subject, such as an anticholinergic, dopaminergic, glutamatergic, histone deacetylase (HDAC) inhibitor, cannabinoid, cysteine ​​protease inhibitor, melatonin, anti-inflammatory agent, hormone (e.g., estrogen or progesterone), or vitamin. In some embodiments, the method comprises administering an agent (e.g., an antidepressant, dopamine agonist, or antipsychotic) to the subject for treating cognitive or behavioral symptoms of a neurological disorder.

[0419] VI. Sequence

[0420]

[0421]

[0422]

[0423]

[0424]

[0425]

[0426] Example

[0427] The following embodiments are included to illustrate specific implementations of this disclosure. Those skilled in the art will understand that the techniques disclosed in the following embodiments represent techniques that work well in the practice of this disclosure and can therefore be considered as specific patterns constituting its practice. However, those skilled in the art will understand from this disclosure that many changes can be made to the specific disclosed embodiments without departing from the spirit and scope of this disclosure, still yielding similar or analogous results.

[0428] Example 1. The Aβ-targeting protein binds to oligomeric and fibrillary Aβ, but not to monomeric Aβ.

[0429] To prepare monomeric Aβ peptide, Aβ 1-40The powder (Anaspec, AS-24235) was reconstituted in hexafluoroisopropanol (HFIP) at a concentration of 1 mg / mL. Aβ... 1-40 The samples were divided into 50 μL vials, dried under N2 gas, and then sterilized at -80°C with Aβ. 1-40 The monomer is stored in HFIP in membrane form. To form the monomer, Aβ... 1-40 The membrane HFIP was dissolved in dimethyl sulfoxide (DMSO) and then diluted to the target concentration in assay buffer before use.

[0430] To prepare oligomeric Aβ 1-42 and fibrous Aβ 1-42 The Aβ in HFIP (Anaspec, AS-64129) 1-42 The membrane was resuspended in DMSO at a concentration of 5 mg / mL, and then diluted in PBS at a concentration of 1 mg / mL. This was to facilitate the formation of oligomeric Aβ. 1-42 Aβ diluted in PBS 1-42 Incubate at 37°C for 3 days. This is to form fibrous Aβ. 1-42 Aβ diluted in PBS 1-42 Incubate at 37°C for 7 days, then centrifuge at 14,000 × g for 15 min at 4°C. The fibrous Aβ... 1-42 Dissolved in PBS. Dynamic light scattering (DLS) was used to verify the quality of the Aβ formulation.

[0431] The binding specificity of ATV to Aβ was measured by ELISA (IBL, 27725). Four different ATVs were analyzed.

[0432] 1. ATV35.23.4 顺式LALA It contains an anti-AβIgG AβFab binding domain and an Fc dimer comprising a first Fc polypeptide, the first Fc polypeptide having a TfR binding region (with an affinity for TfR of approximately 600 nM) and L324A and L235A substitutions to reduce FcγR binding (also known as ATV35.23.4). 顺式LALA :Aβ).

[0433] 2.ATV35.23.4 顺式LALAPG It contains an anti-AβIgG AβFab binding domain and an Fc dimer comprising a first Fc polypeptide, the first Fc polypeptide having a TfR binding region (with an affinity for TfR of approximately 600 nM) and L324A, L235A, and P329G substitutions to reduce FcγR binding (also known as ATV35.23.4). 顺式LALAPG :Aβ).

[0434] 3.ATV35.23.3 顺式LALA(Aβ-targeting protein): Contains an anti-Aβ IgG AβFab binding domain and an Fc dimer comprising a first Fc polypeptide with a TfR-binding region (with an affinity for TfR of approximately 1100 nM) and L324A and L235A substitutions to reduce FcγR binding (also known as ATV35.23.3). 顺式LALA :Aβ).

[0435] 4. ATV35.23.3 顺式LALAPG (Aβ-targeting protein): Contains an anti-Aβ IgG AβFab binding domain and an Fc dimer comprising a first Fc polypeptide with a TfR-binding region (with an affinity for TfR of approximately 600 nM) and L324A, L235A, and P329G substitutions to reduce FcγR binding (also known as ATV35.23.3). 顺式LALAPG :Aβ).

[0436] ATV has the configuration shown in Figure 3A (left).

[0437] Anti-AβIgG antibody was used as a control. The Aβ targeting protein contains the antibody-binding domain of the anti-AβIgG antibody. 20 μL of 0.4 nM antibody was mixed with 100 μL of monomeric, oligomeric, or fibrillated Aβ and incubated at 4 °C for 60 min. 100 μL of each solution was added to the pre-coated plate at 4 °C for 60 min. After washing three times with PBS containing 0.05% Tween-20 (PBST), each well was treated with 100 μL of horseradish peroxidase-conjugated goat anti-human antibody for 1 h at room temperature. After washing three times with PBST, 100 μL of TMB chromophore was added to each well, followed by 100 μL of stop solution. ELISA signals were measured using a microplate spectrophotometer (BioTek Neo2). Results ( Figure 1 The results indicate that all tested anti-Aβ antibodies specifically bound to oligo-Aβ to a considerable degree. 1-42 and fibrous Aβ 1-42 And not bound to monomer Aβ 1-40 .

[0438] Example 2. ATV35.23.3 with weaker affinity. 顺式LALA The Aβ molecule has a higher ATV value than ATV35.23.4. 顺式LALA Higher brain exposure to Aβ

[0439] TfR mu / huKI mice received a single IV dose of 25 mg / kg of anti-Aβ or Aβ-targeting proteins (ATV35.23.3 and ATV35.23.4) (n = 4–5 / group). Blood was collected at 30 minutes post-administration, and peripheral blood and fresh brain (post-perfusion) samples were collected and rapidly frozen on days 1, 2, 4, and 7 post-administration to assess huIgG concentrations in plasma and brain lysates. Whole blood was collected on days 1, 2, and 4 to measure reticulocyte counts.

[0440] In TfR mu / hu In KI mice, plasma PK profiles showed that affinity-dependent TfR-mediated clearance resulted in faster clearance of ATV molecule c from plasma following a single IV dose of either anti-Aβ or ATV:Aβ molecule (Fig. 2A). Brain PK profiles indicated that brain concentrations of ATV:Aβ molecule were approximately 4-fold higher at day 1 post-dose, and significantly higher at days 2 and 4 post-dose (ATV35.23.3 only) (Fig. 2B) (two-way ANOVA, Dunnett's post-hoc). Surprisingly, the weaker TfR affinity of ATV:Aβ molecule (ATV35.23.3) was significantly higher. 顺式LALA The variant ATV35.23.4 (Aβ) showed a stronger affinity for TfR than TfR. 顺式LALA Higher Cmax brain concentrations of Aβ did not correlate with the expected relationship between TfR affinity and brain uptake. Circulating reticulocytes in the blood of ATV-treated mice were not different from those in the anti-Aβ group at any time point (Figure 2C) (univariate ANOVA, Dennett post-hoc), indicating that cis-LALA prevents effector-mediated reticulocyte loss.

[0441] In addition, to demonstrate the impact of the LALA mutation, TfR mu / hu KI mice received a single IV dose of 10 mg / kg of anti-Aβ or ATV:Aβ molecules (n = 5 / group).

[0442] In this experiment, three Aβ-targeting proteins were compared with anti-AβIgG antibodies.

[0443] 1. ATV35.23.3: An Fc dimer containing an anti-AβIgG AβFab binding domain and a first Fc polypeptide with a TfR binding region (with an affinity for TfR of about 1100 nM) (also known as ATV35.23.3:Aβ).

[0444] 2.ATV35.23.3 顺式LALA(Aβ-targeting protein): Contains an anti-Aβ IgG AβFab binding domain and an Fc dimer comprising a first Fc polypeptide with a TfR-binding region (with an affinity for TfR of approximately 1100 nM) and L324A and L235A substitutions to reduce FcγR binding (also known as ATV35.23.3). 顺式LALA :Aβ).

[0445] 3.ATV35.23.3 LALA (Aβ-targeting protein): An Fc dimer (also known as ATV35.23.3) containing an anti-Aβ IgG AβFab binding domain and a first Fc polypeptide with a TfR-binding region (with an affinity for TfR of approximately 1100 nM) and L324A and L235A substitutions to reduce FcγR binding, and a second Fc polypeptide with L324A and L235A substitutions to reduce FcγR binding. LALA :Aβ).

[0446] Peripheral blood and fresh brain (post-perfusion) were collected 24 h after drug administration and rapidly frozen to assess huIgG concentrations in plasma and brain lysates. Fresh bone marrow from the femur was collected, stained for Ter119 (erythroid lineage) and CD44, and reticulocyte populations were determined using flow cytometry. Peripheral whole blood was also collected to measure reticulocytes.

[0447] As expected, peripheral plasma showed similar exposure to all ATVs and lower huIgG concentrations compared to anti-Aβ (Fig. 2D), while the brain showed higher concentrations of ATVs compared to anti-Aβ (Fig. 2E). Blood reticulocytes showed significant loss after treatment with ATV35.23.3:Aβ, an effector-positive cell with the WT Fc region, compared to anti-Aβ, but a single cis-LAL A mutation (ATV35.23.3) was observed. 顺式LALA (Aβ) or two LALA mutations (ATV: 35.23.3) LALA The :Aβ variant completely prevented reticulocyte loss (Fig. 2F). Similarly, bone marrow reticulocytes showed cell loss only in effector-positive ATV35.23.3:Aβ variants with WT Fc (Fig. 2G), indicating that this architecture enables TfR-mediated reticulocyte cytotoxicity, while cis-LALA and LALA mutations appear to completely prevent this.

[0448] Example 3. Comparison of brain uptake and blood reticulocytes in ATV and C-terminal TfR Fab types.

[0449] TfR mu / huKI mice received a single IV dose of 10 mg / kg of anti-Aβ and ATV:Aβ (Fig. 3A, left) or an anti-Aβ TfRFab fusion molecule (Fig. 3A, right) (n = 5 / group). The molecule in the right figure is a fusion of anti-Aβ IgG with WT Fc and a Fab fragment bound to TfR. The two molecules showed similar affinity for TfR (left and right figures). Peripheral blood and fresh brain (post-perfusion) were collected 24 h after administration and rapidly frozen to assess circulating reticulocyte counts in whole blood and brain huIgG concentrations. The TfR-targeting molecule showed brain concentrations similar to those expected for the matched TfR affinity (Fig. 3B). However, circulating reticulocytes showed a significant reduction under anti-AβTfR Fab fusion molecule (one-way ANOVA, Dunnett post-hoc), while ATV:Aβ did not (Fig. 3C), indicating that cis-LALA better prevents effector-mediated reticulocyte loss and is associated with anti-AβTfR Fab (TfR) fusion molecule. C 端Fab Compared to :Aβ) fusion molecules, it has an improved blood safety profile.

[0450] Example 4. App SAA KITfR mu / hu PK profile and plaque microglia recruitment in KI mice.

[0451] ATV35.23.3 顺式LALA Aβ and ATV35.23.4 顺式LALA Compared to Aβ, it showed improved brain exposure, plaque immune decoration, and plaque reduction after a single dose.

[0452] App SAA KI; TfR mu / huKI mice received a single IV dose of 10 mg / kg of anti-Aβ or ATV:Aβ molecules (n = 4-5 / group). Peripheral blood and fresh brain (post-perfusion) were collected at 2, 7, and 14 days post-administration and rapidly frozen to assess huIgG concentrations in plasma and brain lysates. One fresh brain hemisphere from each animal was fixed by immersion at 4°C for approximately 24 h for immunohistochemistry. Three to four replicate sagittal brain sections (40 μm) were selected from each animal and incubated in blocking buffer at 4°C overnight with primary / secondary antibodies (CD68, Biorad, MCA1957; Aβ, IBLAmerica 18584; and donkey anti-hu IgG, Jackson, 709-606-149). After washing, the sections were incubated with secondary antibodies (donkey anti-rat, Invitrogen, SA5-10027; donkey anti-rabbit, Invitrogen, A21206) and DAPI (5 μg / mL, Invitrogen, D1306). After washing, the sections were stained with Prolong Glass (Invitrogen, P36984). Slides were imaged at 20x magnification using a Zeiss Axioscan.Z1 slide scanner, and processed in Zeiss ZEN software using custom macros to generate binary masks with dynamic thresholds for each channel of interest (Aβ, huIgG, CD68, and tissue regions using DAPI). Data analysis was performed using Microsoft Excel and GraphPadPrism 9.

[0453] With TfR mu / hu Similar results were observed in KI mice, App SAA KI TfR mu / hu Plasma PK profiles in KI mice showed TfR-mediated clearance following a single IV dose of anti-Aβ or ATV:Aβ molecules (Fig. 4A). ATV showed approximately 4-5 times higher brain concentrations at 24 h compared to anti-Aβ (Fig. 4B). [The text abruptly ends here, likely due to an incomplete translation or missing information.] mu / hu Consistent with observations in KI mice, and with ATV35.23.4 顺式LALA Compared to Aβ, ATV35.23.3 顺式LALAAβ produced higher brain concentrations (Fig. 4B). ATV and anti-Aβ also showed that huIgG signaling localized to plaques, and immune decoration was well correlated with overall brain exposure, showing higher levels of ATV at 48 h post-dose. Compared to the more affinity ATV:Aβ, the less affinity ATV:Aβ showed a trend toward higher plaque decoration (Fig. 4C), consistent with brain ELISA data, but unexpected based on the established TfR affinity-brain concentration relationship. ATVs showed that they effectively recruited CD68-positive microglia to plaques by increasing the overlap of CD68 signaling within and around the plaques to approximately twice that of juveniles (Fig. 4D). Recruiting microglia to plaques plays an important role for Aβ therapeutics and enables them to phagocytose plaques. Functionally, this leads to a reduction in Aβ plaques in the brain; in fact, ATV35.23.3 顺式LALA Aβ showed the greatest reduction in plaque, with a reduction of approximately 34% two days after administration and 49% one week after administration, again consistent with the highest brain exposure (Figure 4E).

[0454] Example 5. PK profile in WTC57BL / 6J mice.

[0455] WT C57BL / 6J KI mice received a single IV dose of 10 mg / kg of ATV:Aβ molecules (ATV35.23.4). 顺式LALA :Aβ、ATV35.23.3 顺式LALA :Aβ、ATV35.23.4 顺式LA LAPG Aβ and ATV35.23.3 顺式LALAPG (n = 3 / group / time point). Fresh (in-life) or peripheral blood was collected at multiple time points to assess plasma huIgG concentration. Both ATV:Aβ molecules showed similar clearance and PK profiles in WT mice, and the lack of TfR binding to murine TfR in these molecules indicates a lack of nonspecific binding in the absence of target binding. cis-LALA and cis-LALAPG molecules showed similar performance in WT mice (Table 5A and 5B). Figure 5 ).

[0456] Table 5A.

[0457]

[0458] Example 6. Phagocytosis of isolated microglia revealed that ATV35.23.3 compared to anti-Aβ. 顺式LALA Aβ has a comparable ability to promote the phagocytosis of β-amyloid protein.

[0459] To generate FAM (fluorescein-labeled) β-amyloid fibrils, FAM-labeled β-amyloid protein (1-42) (0.5 mg, AnaspecAS-23525-05) was resuspended in 100 μL DMSO and then diluted to 100 μM with 1 mL PBS. The solution was incubated at 37 °C with shaking for 24 h. The FAM-β-amyloid fibrils were then transferred to 1.5 mL ultracentrifuge tubes and centrifuged at 100,000 × g for 30 min at 4 °C. The supernatant was discarded, and the precipitate was resuspended in 1 mL PBS, followed by large-volume pipetting. The ultracentrifugation step was repeated, followed by two rounds of washing. Finally, the precipitate was resuspended in 111 μL PBS and stored at -80 °C.

[0460] Dynamic light scattering (DLS) confirmed the identity of the β-amyloid aggregates. In short, 30 μL of β-amyloid aggregates (1 mg / mL) were loaded onto 384-well plates (black, clear bottom, Costa). A plate cap was used to protect the bottom of the plate from dust and scratches that could affect DLS readings. The plate was then sealed with a membrane and centrifuged at 1000 rpm for 5 min to allow the solution to settle to the bottom and eliminate air bubbles. Readings were then performed at 25°C using a DynaPro plate reader III (Wyatt Technology) and Dynamics v7 software, with each well read for 5 seconds, averaging 10 measurements. DLS results revealed that the generated FAM-β-amyloid 1-42 fibrils consisted of a heterogeneous mixture of monomers, oligomers, and fibrils. Figure 6A and Figure 6A ).

[0461] Table 6A.

[0462]

[0463] To conduct an in vitro microglia phagocytosis experiment, immature TfR cells were perfused with 1×PBS. mu / hu KI (3 months old, male) were used for single-cell dissociation of their brains. The Adult Brain Dissociation Kit (Miltenyi Biotec, 130-107-677) and gentleMACS were followed according to the kit instructions. TMCells were dissociated using Octo dissociation agent. Excess debris and myelin were removed using the kit's debris removal solution, and the final cell pellet was resuspended in 200 μL of dPBS (containing calcium and magnesium) with 0.5% BSA. The number of viable microglia in each sample was then quantified using the following steps: A small fraction of cells from each sample were stained for 15 min at 4°C with Cd11b-BV421 (BioLegend 101251, 1:100), CD45-APC (BD Biosciences catalog 559864, 1:100), and Fc blocking solution (BioLegend 101320, 1:100), followed by washing and resuspending in FACS buffer (1% BSA + 1 mM EDTA in PBS) containing propidium iodide (PI) (Miltenyi Biotec, 130-093-233). Next, the cell fractions were mixed with CountBright Plus absolute counting beads (Invitrogen, Ref C36995) and loaded onto a BD FACSAriaIII sorter to quantify the total number of viable microglia in each sample. Cells from the same animals were divided into treatment groups, each containing 50,000 cells treated with 10 nM IgG, anti-Aβ, and ATV. 顺式LALA :Aβ, ATV:Aβ or ATV LALA Live microglia treated with Aβ and 100 nM FAM-labeled β-amyloid fibrils and incubated at 37°C for 45 min ( Figure 6B Control samples were treated with 10 nM of the corresponding antibody and 100 nM of FAM-Aβ fibrils, but incubated at 4 °C for 30 min instead. After these incubations, the treated samples were washed and stained at 4 °C for 15 min with Cd11b-BV421 (BioLegend 101251, 1:100), CD45-APC (BD Pharmingen, 1:100), and Fc blocking solution (BioLegend 101320, 1:100), followed by washing and resuspending in FACS buffer containing PI. On a sorter, 10,000 viable microglia and the intensity of the FAM signal were recorded for each treated sample. To quantify the FAM signal intensity of each viable microglia, analysis was performed on FlowJo 10.8.1.

[0464] The results revealed a significant increase in the percentage of microglia treated with anti-Aβ antibody compared to control IgG (Figure 6C). Interestingly, compared to both anti-Aβ and ATV:Aβ, ATV... 顺式LALA Aβ had the same ability to promote the phagocytosis of β-amyloid (Figure 6C) (one-way ANOVA, paired analysis). In contrast, it was similar to ATV.顺式LALA Compared to Aβ, ATV has effectors on both Fc chains that alleviate LALA mutations. LALA Aβ promotes significantly reduced microglia phagocytosis (Fig. 6C) (one-way ANOVA, paired analysis). The mean fluorescence intensity of the FAM-Aβ signal per viable microglia indicates that, compared with anti-Aβ and ATV:Aβ, ATV:Aβ significantly reduces microglia phagocytosis. 顺式LALA Aβ promotes the uptake of the same level of β-amyloid protein in microglia, while ATV has no effect on the entire cell. LALA Aβ significantly reduced the amount of Aβ engulfed (Figure 6D). These results reveal that cis-LALA mutations do not reduce ATV. 顺式LALA Aβ's ability to trigger microglia phagocytosis.

[0465] Example 7. APP SAA KI; TfR mu / hu Single-dose immune decoration and microglia recruitment in KI mice demonstrate the effectiveness of cis-LALA molecules.

[0466] APP SAA KI; TfR mu / hu KI mice received a single IV dose of 3 mg / kg control IgG, 3 mg / kg ATV:Aβ, or 2 mg / kg ATV. 顺式LALA Aβ, 3mg / kg ATV LALA Anti-Aβ or 7 mg / kg anti-Aβ (n = 8 / group). Fresh brains were collected 7 days after administration following perfusion. These dose levels achieved approximately equivalent anti-Aβ and ATV:Aβ brain concentrations at the final time point. Additionally, as described above, one perfused fresh brain hemisphere from each animal was soaked and fixed for immunohistochemistry and image quantification.

[0467] The results, as expected, revealed the equivalent brain coverage of huIgG for each plaque area, as shown by immunodecoration analysis (Figure 7A). Interestingly, despite carrying a copy of the LALA mutation, ATV... 顺式LALA Aβ can still recruit activated microglia to plaques, similar to both ATV:Aβ and anti-Aβ. However, ATV carrying two LALA mutant copies... LALA Aβ showed a reducing ability (Figure 7B). The ability of each molecule to recruit microglia to different sizes (30–125, 125–250, 250–500, and >500 μm) was also analyzed. 2 The ability of ATV to detect β-amyloid plaques. The results revealed ATV's ability to detect β-amyloid plaques. 顺式LALAAβ's ability to recruit activated microglia to β-amyloid plaques of various sizes was consistent with both anti-Aβ and ATV:Aβ. By assessing the total plaque area level in each group, we observed similarities to both anti-Aβ and ATV:Aβ. 顺式LALA Aβ promotes a significant reduction in plaque levels (Figures 7C-D). This is also evident when using plaque counts and analyses of β-amyloid plaques of various sizes. These results collectively reveal that ATV... 顺式LALA Aβ maintains the ability to recruit microglia to plaques and reduces plaques at a level similar to that of anti-Aβ. In contrast, ATV... LALA Aβ is impaired in recruiting microglia and reducing plaques.

[0468] Example 8. Cis-LALA reduces TFR-mediated in vivo hematologic tendency in non-human primates (NHP).

[0469] Crab-eating macaques received an IV dose of 15 or 50 mg / kg of anti-Aβ or ATV:Aβ molecules on days 1, 15, and 29 (e.g., every two weeks). Blood samples were collected one week before administration and on days 8, 15 (before the day 15 dose), 29 (before the day 29 dose), and 31 for hematological purposes.

[0470] Consistent with previous data, a dose-dependent acute decrease in circulating reticulocytes and TfR affinity was observed (Fig. 8A). Minimal effects on circulating RBCs and heme were observed after 4 weeks of exposure, and no difference was observed between cis-LALA and cis-LALAPGATV:Aβ molecules (Fig. 8B-C). These data suggest that multiple administrations of ATV have a favorable safety profile in NHP.

[0471] Example 9. PK of a single dose of ATV:Aβ in cynomolgus monkeys.

[0472] Cynomolgus monkeys received a single intravenous dose of 6 mg / kg of anti-Aβ or ATV:Aβ molecules. Blood samples were collected at different time points to measure huIgG concentrations. ATV35.23.3 顺式LALA Aβ and ATV35.23.3 顺式LALAPG The area under the curve (AUC) and clearance rate of Aβ were similar to those of the anti-Aβ control group in non-human primates. Figure 9 ATV35.23.4 顺式LALA Aβ and ATV35.23.4 顺式LALAPG Aβ is cleared slightly faster than anti-Aβ.

[0473] Example 10.5XFAD; PK profile and plaque microglia recruitment of ATVs with cisLALA or cisLALAPG mutations in TfRmu / hu KI mice.

[0474] 5XFAD; TfR mu / hu KI mice received four intraperitoneal (IP) doses (q3d, i.e., days 0, 3, 6, and 9) of ATV35.23.4. 顺式LALA ATV35.23.4 顺式LALAPG Alternatively, control IgG (n = 15 / group). Fresh plasma was collected from n = 3 mice per group at each time point. Peripheral blood and fresh brain (post-perfusion) were collected from all animals 12 days after administration and rapidly frozen to assess huIgG concentrations in plasma and brain lysates. One fresh brain hemisphere from each animal was fixed by immersion at 4°C for approximately 24 h for immunohistochemistry. Three to four replicate sagittal brain sections (40 μm) were selected from each animal and incubated overnight at 4°C with primary / secondary antibodies (CD68, Biorad, MCA1957; Aβ, IBL America 18584; and donkey anti-huIgG, Jackson, 709-606-149) in blocking buffer, followed by washing and incubation with secondary antibodies (donkey anti-rat, Invitrogen, SA5-10027; donkey anti-rabbit, Invitrogen, A21206) and DAPI (5 μg / mL, Invitrogen, D1306), then washed and stained with Prolong Glass (Invitrogen, P36984). Slides were imaged at 20x magnification using a Zeiss Axioscan.Z1 slide scanner, and processed in Zeiss ZEN software using custom macros to generate binary masks with dynamic thresholds for each channel of interest (Aβ, huIgG, CD68, and tissue regions using DAPI). Data analysis was performed using Microsoft Excel and GraphPad Prism 9.

[0475] 5XFAD; TfR mu / hu Plasma PK profile in KI mice at ATV35.23.4 顺式LALA Compared to ATV35.23.4 顺式LALAPG The results were consistent and showed the expected TfR-mediated clearance compared to control IgG. Figure 10A The brain concentrations of ATV were also similar (Figure 10B), indicating that different cisLALAPG mutations generally do not affect plasma clearance or brain uptake compared to cisLALA mutations.

[0476] The relatively low dose used was intended to avoid reaching the upper limit effect; this would allow for the detection of minute differences in microglial recruitment (indicating Fc-mediated responses) between Fc mutations on ATV. Given the acute nature of the study, this endpoint focused on the smallest plaques, as the expected time was insufficient to produce substantial responses around larger plaques. Immunodecoction of both ATVs was equivalent across all plaques (Figure 10C), consistent with overall brain huIgG concentrations. Interestingly, ATV35.23.4 顺式LALAPG Displayed as ATV35.23.4 顺式LALA The considerable ability to recruit microglia to small plaques (Fig. 10D) indicates that additional effector silencing mutations do not affect microglia recruitment. This suggests that asymmetric engineering still allows the molecule to retain essentially complete Fab-mediated effector function.

[0477] Example 11. Safety study of ARIA in 5XFAD;TfRmu / huKI mice.

[0478] 5xFAD:TfRmu / huKI mice (male and female, 10-12 months old at the start of the study) were assigned to five treatment groups (n=10): anti-Aβ (10 mg / kg, n=6M, 4F), anti-Aβ with LALA mutation (10 mg / kg, n=6M, 4F), ATV35.23.3:Aβ (3 mg / kg, n=6M, 3F), ATV35.23.3 cis-LALA:Aβ (3 mg / kg, n=4M, 4F), and naive (n=3M, 2F).

[0479] All treatments were administered weekly via intraperitoneal (ip) for 10 weeks. MRI images were first collected at baseline before treatment began, and again 1–3 days after weekly administration. Blood was collected from all animals before the first dose. Imaging was performed only on juvenile animals at baseline and after the 10th dose. Anti-CD4 antibodies were administered ip every two weeks, starting one day before the first administration of the compound (0.5 mg / animal). At the end of the study, blood was collected before the 10th and final doses and 24 hours after the final dose at sacrifice.

[0480] Analysis of weekly MRI scans showed MRI lesions consistent with ARIA-E and ARIA-H in 8 / 10 animals in the anti-Aβ group and 3 / 10 animals in the Aβ group with LALA mutations. ARIA was not detected in either of the two ATV treatment groups. Figure 11 ).

[0481] MRI lesions detected using T2w sequences are either located in the meninges surrounding the brain (convex high-density signal) or deep within the cortex (cortical high-density signal, diffuse or localized). MRI lesions detected using T2* sequences appear as localized low-density signals in the meninges or cortex. Potential pathological features include meningeal vascular inflammation and microvascular damage (visible using H&E staining), protein fluid leakage (visible via immunohistochemistry of albumin and / or mouse IgG), and the presence of microbleeds (visible using Perls staining).

[0482] The analysis of MRI scans and histological sections was performed independently by different observers who were unaware of the treatment allocation.

[0483] A separate experiment was conducted to assess the pathway by which ATV-Aβ enters the brain. Figure 12 As shown, mice treated with a single dose of ATV35.23.3 cis-LALA:Aβ exhibited less angiogenesis binding compared to mice treated with a single dose of anti-Aβ. These results demonstrate a different pathway into the brain, which may contribute to a reduced incidence of ARIA events.

Claims

1. An Aβ-targeting protein comprising: (a) β-amyloid (Aβ) binding region; (b) The transferrin receptor (TfR) binding region, which specifically binds to TfR with an affinity of about 900 nM to about 10,000 nM; and (c) Fcγ receptor (FcγR) binding region.

2. The Aβ-targeting protein of claim 1, wherein the TfR binding region specifically binds to TfR with an affinity of about 900 nM to about 2500 nM.

3. The Aβ-targeting protein of claim 1, wherein the TfR binding region specifically binds to TfR with an affinity of about 900 nM to about 1300 nM.

4. The Aβ-targeting protein of claim 3, wherein the TfR-binding region specifically binds to TfR with an affinity of about 1100 nM.

5. The Aβ-targeting protein according to any one of claims 1-4, wherein the TfR binding region binds to the apical domain of the TfR.

6. The Aβ-targeting protein according to any one of claims 1-5, wherein the TfR-binding region binds to the TfR without inhibiting the binding of transferrin to the TfR.

7. The Aβ-targeting protein according to any one of claims 1-6, wherein the Aβ-targeting protein is capable of active trans-blood-brain barrier delivery.

8. The Aβ-targeting protein according to any one of claims 1-7, wherein the TfR binding region comprises: (a) TfR-binding peptide; (b) A TfR-binding polypeptide linked to an Fc polypeptide; (c) A first Fc polypeptide containing a CH3 domain modified to bind TfR; (d) Anti-TfR antibody or its antigen-binding fragment; or (e) Anti-TfR antibody or its antigen-binding fragment linked to the Fc polypeptide.

9. The Aβ-targeting protein of any one of claims 1-8, wherein the FcγR binding region comprises a second Fc polypeptide, optionally wherein the second Fc polypeptide does not contain any modifications that reduce FcγR binding.

10. The Aβ-targeting protein of claim 9, wherein the Aβ-targeting protein comprises an Fc dimer.

11. The Aβ-targeting protein of claim 10, wherein the Fc dimer comprises: (a) the first Fc polypeptide; and (b) The second Fc polypeptide.

12. The Aβ-targeting protein of any one of claims 8-11, wherein the first Fc polypeptide, the second Fc polypeptide, or the first Fc polypeptide and the second Fc polypeptide are derived from human IgG1, IgG2, IgG3, or IgG4.

13. The Aβ-targeting protein according to any one of claims 8-12, wherein, according to the EU numbering scheme, the modified CH3 domain comprises amino acid substitutions of 384Y, 386T, 387E, 388W, 389V, 413T, 415E, 416E, and 421F.

14. The Aβ-targeting protein of any one of claims 8-10 and 12-13, wherein the anti-TfR antibody or its antigen-binding fragment comprises: an antibody, an F(ab)2 fragment, a Fab fragment, or a single-chain variable fragment (scFv).

15. The Aβ-targeting protein according to any one of claims 1-14, wherein when the Aβ-targeting protein binds to the TfR, the Aβ-targeting protein has reduced binding to the FcγR.

16. The Aβ-targeting protein of any one of claims 9-15, wherein the Fc dimer comprises the first Fc polypeptide, wherein the first Fc polypeptide comprises one or more amino acid substitutions that reduce binding to FcγR; and the second Fc polypeptide, wherein the second Fc polypeptide does not contain any modifications that reduce FcγR binding.

17. The Aβ-targeting protein of claim 16, wherein, according to the EU numbering scheme, the one or more amino acid substitutions that reduce binding to the FcγR comprise 234A and 235A substitutions.

18. The Aβ-targeting protein of claim 16 or 17, wherein, according to the EU numbering scheme, the one or more amino acid substitutions that reduce binding to the FcγR comprise a 329G substitution.

19. The Aβ-targeting protein of claim 16, wherein, according to the EU numbering scheme, the one or more amino acid substitutions that reduce binding to the FcγR comprise 234A, 235A, and 329G substitutions.

20. The Aβ-targeting protein of any one of claims 10-19, wherein the Fc dimer comprises one or more heterodimerization mutations.

21. The Aβ-targeting protein of claim 20, wherein the first Fc polypeptide comprises a club-shaped mutation and the second Fc polypeptide comprises a mortise-shaped mutation, or wherein the first Fc polypeptide comprises a mortise-shaped mutation and the second Fc polypeptide comprises a club-shaped mutation.

22. The Aβ-targeting protein of claim 21, wherein, according to the EU numbering scheme, the mortar mutation comprises a T366W substitution; and according to the EU numbering scheme, the mortar mutation comprises T366S, T368A, and Y407V substitutions.

23. The Aβ-targeting protein of claim 22, wherein, according to the EU numbering scheme, the first Fc polypeptide comprises T366S, T368A, and Y407V substitutions; and according to the EU numbering scheme, the second Fc polypeptide comprises T366W substitution.

24. The Aβ-targeting protein of claim 22, wherein, according to the EU numbering scheme, the first Fc polypeptide comprises a T366W substitution; and according to the EU numbering scheme, the second Fc polypeptide comprises T366S, T368A, and Y407V substitutions.

25. The Aβ-targeting protein of claim 24, wherein the modified CH3 domain of the first Fc polypeptide has at least 85%, at least 90%, or at least 95% similarity to amino acids 348-454 of any one of SEQ ID NO: 8, 10, and 17-31.

26. The Aβ-targeting protein of claim 25, wherein the modified CH3 domain comprises the amino acid sequence of amino acid 348-453 or 348-454 of any one of SEQ ID NO: 8, 10 and 17-31.

27. The Aβ-targeting protein of claims 24-26, wherein the first Fc polypeptide has at least 85%, at least 90%, or at least 95% similarity to amino acids 228-454 of any one of SEQ ID NO:8, 10, and 17-31.

28. The Aβ-targeting protein of claim 27, wherein the first Fc polypeptide comprises the amino acid sequence of amino acid 228-453 or 228-454 of any one of SEQ ID NO: 8, 10 and 17-31.

29. The Aβ-targeting protein of any one of claims 24-27, wherein the second Fc polypeptide has at least 85%, at least 90%, or at least 95% similarity to amino acids 228-454 of SEQ ID NO:

9.

30. The Aβ-targeting protein of claim 29, wherein the second Fc polypeptide comprises the amino acid sequence of amino acids 228-453 or 228-454 of SEQ ID NO:

9.

31. The Aβ-targeting protein according to any one of claims 1-30, wherein the Aβ-binding region comprises an anti-Aβ antibody or an antigen-binding fragment thereof.

32. The Aβ-targeting protein of claim 31, wherein the anti-Aβ antibody or its antigen-binding fragment comprises: at least one Fab region, at least two Fab regions, an F(ab)2 region, or at least one scFv.

33. The Aβ-targeting protein of claim 31 or 32, wherein the anti-Aβ antibody or its antigen-binding fragment comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: (a) The VH comprises a first heavy chain complementarity-determining region (VHCDR1) having the amino acid sequence of SEQ ID NO:1, a second heavy chain complementarity-determining region (VHCDR2) having the amino acid sequence of SEQ ID NO:2, and a third heavy chain complementarity-determining region (VHCDR3) having the amino acid sequence of SEQ ID NO:3; and (b) The VL comprises a first light chain complementarity-determining region (VLCDR1) having the amino acid sequence of SEQ ID NO:4, a second light chain complementarity-determining region (VLCDR2) having the amino acid sequence of SEQ ID NO:5, and a third light chain complementarity-determining region (VLCDR3) having the amino acid sequence of SEQ ID NO:

6.

34. The Aβ-targeting protein of claim 33, wherein the VH comprises an amino acid sequence having at least 85%, at least 90%, or at least 95% identity with amino acids 1-120 of SEQ ID NO:8 or 10, and the VL comprises an amino acid sequence having at least 85%, at least 90%, or at least 95% identity with amino acids 1-109 of SEQ ID NO:

7.

35. The Aβ-targeting protein of claim 34, wherein the VH comprises the amino acid sequence of amino acids 1-120 of SEQ ID NO:8 or 10 and the VL comprises the amino acid sequence of amino acids 1-109 of SEQ ID NO:

7.

36. The Aβ-targeting protein of claim 33, wherein the anti-Aβ antibody or its antigen-binding fragment comprises two heavy chain Fab regions and two light chain Fab regions, wherein each heavy chain Fab region comprises an amino acid sequence having at least 85%, at least 90%, or at least 95% identity with amino acids 1-227 of SEQ ID NO:8 or 10, and each light chain Fab region comprises an amino acid sequence having at least 85%, at least 90%, or at least 95% identity with amino acids of SEQ ID NO:

7.

37. The Aβ-targeting protein of claim 36, wherein each heavy chain Fab region comprises the amino acid sequence of amino acids 1-227 of SEQ ID NO:8 or 10, and each light chain Fab region comprises the amino acid sequence of SEQ ID NO:

7.

38. The Aβ-targeting protein according to any one of claims 1-37, wherein the Aβ-targeting protein comprises: (a) A first light chain comprising an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to SEQ ID NO:7; (b) A first heavy chain comprising an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to SEQ ID NO:8 or 10; (c) A second light chain comprising an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to SEQ ID NO:7; and (d) A second chain comprising an amino acid sequence having at least 85%, at least 90%, or at least 95% similarity to SEQ ID NO:

9.

39. The Aβ-targeting protein as described in claim 38, wherein: (a) The first light chain contains the amino acid sequence of SEQ ID NO:7; (b) The first heavy chain comprises the amino acid sequence of SEQ ID NO:8 or 10, optionally wherein the C-terminal lysine is removed; (c) The second light chain comprises the amino acid sequence of SEQ ID NO:7; and (d) The second heavy chain comprises the amino acid sequence of SEQ ID NO:9, optionally wherein the C-terminal lysine is removed.

40. The Aβ-targeting protein of any one of claims 1-39, wherein the Aβ-targeting protein binds to amyloid plaques, cerebral vascular Aβ, or diffuse Aβ deposits.

41. The Aβ-targeting protein according to any one of claims 1-40, wherein the Aβ-targeting protein does not deplete reticulocytes in vivo.

42. A composition comprising the Aβ-targeting protein as described in any one of claims 1-41.

43. A pharmaceutical composition comprising the Aβ-targeting protein as described in any one of claims 1-41 or the composition as described in claim 42 and a pharmaceutically acceptable excipient.

44. The pharmaceutical composition of claim 43, wherein the pharmaceutical composition further comprises an additional agent that can be used to treat Alzheimer's disease.

45. The pharmaceutical composition of claim 43, wherein the pharmaceutical composition is formulated for use in combination with an additional agent that can be used to treat Alzheimer's disease.

46. ​​A method for reducing amyloid plaques in the brain of a subject, the method comprising administering to the subject an Aβ-targeting protein as described in any one of claims 1-41, or a composition as described in claim 42, or a pharmaceutical composition as described in any one of claims 43-45.

47. The method of claim 46, wherein the subject has cognitive impairment, memory loss, dementia, or loss of neuronal connections in the brain.

48. The method of claim 46 or 47, wherein the subject has a disease associated with amyloid plaque accumulation or is at risk of developing said disease.

49. The method of any one of claims 46-48, wherein the subject has or has been diagnosed with Alzheimer's disease or is at increased risk of developing Alzheimer's disease.

50. A method of treating a subject with a neurodegenerative disease, comprising administering to the subject an Aβ-targeting protein as described in any one of claims 1-41, a composition as described in claim 42, or a pharmaceutical composition as described in any one of claims 43-45.

51. The method of claim 50, wherein the neurodegenerative disease is Alzheimer's disease.

52. The method of any one of claims 46-51, wherein the method further comprises administering to the subject at least one additional agent that can be used to treat Alzheimer's disease.

53. The pharmaceutical composition according to any one of claims 43-45, for the treatment of Alzheimer's disease.

54. The pharmaceutical composition of any one of claims 43-45, for enhancing Aβ phagocytosis and / or increasing the recruitment of microglia to Aβ-positive plaques in a subject.

55. A nucleic acid encoding an Aβ-targeting protein as described in any one of claims 1-41.

56. A nucleic acid encoding a polypeptide having at least 85%, at least 90%, or at least 95% similarity to any one of SEQ ID NO: 8, 10, and 17-31, wherein, according to the EU numbering scheme, the encoded polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 as shown in Table 1.

57. The nucleic acid of claim 56, wherein the encoded polypeptide comprises: (a) Alanine at position 234 and alanine at position 235; (b) Glycine at position 329; (c) Alanine at position 234, alanine at position 235, and glycine at position 329; (d) Tryptophan at position 366; (e) Serine at position 366, alanine at position 368, and valine at position 407; (f) Alanine at position 234, alanine at position 235, and tryptophan at position 366; (g) Glycine at position 329 and tryptophan at position 366; (h) alanine at position 234, alanine at position 235, glycine at position 329, and tryptophan at position 366; (i) Alanine at position 234, alanine at position 235, serine at position 366, alanine at position 368 and valine at position 407; (j) Glycine at position 329, serine at position 366, alanine at position 368, and valine at position 407; or (k) alanine at position 234, alanine at position 235, glycine at position 329, serine at position 366, alanine at position 368, and valine at position 407. Each position is based on the EU numbering scheme.

58. The nucleic acid of claim 57, wherein the encoded polypeptide has an amino acid sequence of any one of SEQ ID NO: 8, 10 and 17-31, optionally wherein, according to the EU numbering scheme, the polypeptide has glycine at position 329 and / or tryptophan at position 366.

59. A combination of nucleic acids comprising: a first nucleic acid encoding a first polypeptide having an amino acid sequence having any one of SEQ ID NO:8, 10 and 17-31, and a second nucleic acid encoding a second polypeptide having an amino acid sequence having SEQ ID NO:

9.

60. The combination of claim 59, wherein the combination further comprises a third nucleic acid encoding a third polypeptide having the amino acid sequence of SEQ ID NO:

7.

61. A method for producing an Aβ-targeting protein, the method comprising: (a) culturing recombinant host cells containing one or more nucleic acids encoding the Aβ-targeting protein as described in any one of claims 1-41; and (b) Isolate the Aβ-targeting protein from the culture.

62. A cell that expresses the Aβ-targeting protein as described in any one of claims 1-41.

63. The cell of claim 62, wherein the cell comprises: (a) A first nucleic acid encoding a first polypeptide having at least 85%, at least 90%, at least 95%, or 100% similarity to any one of SEQ ID NO: 8, 10, and 17-31, wherein, according to the EU numbering scheme, the encoded polypeptide has amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 as shown in Table 1; (b) a second nucleic acid encoding a second polypeptide having at least 85%, at least 90%, at least 95%, or 100% similarity to SEQ ID NO:9; and (c) A third nucleic acid that encodes a third polypeptide having at least 85%, at least 90%, at least 95%, or 100% similarity to SEQ ID NO:

7.

64. The cell of claim 63, wherein the first polypeptide comprises: (a) Alanine at position 234 and alanine at position 235; (b) Glycine at position 329; (c) Alanine at position 234, alanine at position 235, and glycine at position 329; (d) Tryptophan at position 366; (e) Alanine at position 234, alanine at position 235, and tryptophan at position 366; (f) Glycine at position 329 and tryptophan at position 366; (g) alanine at position 234, alanine at position 235, glycine at position 329, and tryptophan at position 366; Each position is based on the EU numbering scheme.

Citation Information

Patent Citations

  • Road Lighting Street Lighting Pole (1)

    CN3334662D

  • Unconjugated Anti-TfR Antibodies and Compositions Thereof for the Treatment of Cancer

    US20130028891A1

  • Anti-transferrin receptor antibodies with tailored affinity

    US20180282408A1

  • ANTI-TfR ANTIBODIES AND THEIR USE IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS

    US20190092870A1

  • Monovalent blood brain barrier shuttle modules

    US20200071413A1